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Aceito o desafio. 
Que poeta se nega 
A um aceno do acaso? 
Tenho o prazo 
Acabado, 
O que vier é ganho. 
Na lonjura 
Da última aventura 
É que a alma revela o seu tamanho. 
 
Miguel Torga 
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Abstract 
Growing evidence implicates aberrant lipid signaling in Alzheimer‟s disease (AD). While phospholipases 
A2 and C have been recently shown to mediate key actions of amyloid β-peptide (Aβ) through a 
dysregulation of arachidonic acid and phosphatidylinositol-4,5-bisphosphate metabolism, respectively, 
the role of phospholipase D (PLD) has so far remained elusive. PLD produces phosphatidic acid (PA), a 
bioactive lipid involved in multiple aspects of cell physiology, including signaling and membrane 
trafficking processes. Here we show that oligomeric Aβ enhances PLD activity in cultured neurons and 
that this stimulatory effect does not occur upon ablation of PLD2 via gene targeting. Aβ fails to 
suppress long-term potentiation in PLD2-deficient hippocampal slices, suggesting that PLD2 is required 
for the synaptotoxic action of this peptide. In vivo PLD activity, as assessed by detection of 
phosphatidylethanol levels using mass spectrometry (MS) following ethanol injection, is also increased 
in the brain of a transgenic mouse model of AD (SwAPP). Furthermore, Pld2 ablation rescues memory 
deficits and confers synaptic protection in SwAPP mice despite a significant Aβ load. MS-based lipid 
analysis of Pld2 mutant brains in the presence or absence of the SwAPP transgene unmasks striking 
crosstalks between different PA species. This lipid analysis shows an exquisite acyl chain specificity and 
plasticity in the perturbation of PA metabolism, with the notable elevation in SwAPP brains of a pool of 
PA previously linked to degeneration. Collectively, our results point to specific molecular species of PA 
as key modulators of AD pathogenesis and identify PLD2 as a novel potential target for therapeutics. 
Moreover we expanded our MS analysis of the Pld2/SwAPP mice to other lipid groups, other than PA. 
We found that overexpression of the SwAPP transgene leads to significant increase in the ganglioside, 
GM3. Remarkably, Pld2 ablation leads to a decrease in GM3 in the non-transgenic background and to a 
rescue to normals in the SwAPP background. This lipidomic analysis uncovered interesting lipid 
signaling crosstalks that are modulated by PLD2 in the context of AD models. 
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Resumo 
Trabalhos anteriores indicam que distúrbios no metabolismo dos lípidos estão relacionados com a 
doença de Alzheimer (AD). Enquanto que as fosfolipases A2 e C foram demonstradas como 
mediadoras das acções do péptido, amilóide beta (Aβ), através da desregulação do metabolismo do 
ácido araquidónico e fosfoinositol-4,5-bifosfato, respectivamente, o papel da fosfolipase D (PLD) 
permanence por esclarecer. A PLD produz ácido fosfatídico (PA), um lípido envolvido em múltiplos 
aspectos da fisiologia cellular, como vias de sinalização e tráfico membranar. Neste trabalho, 
mostramos que oligómeros de Aβ levam a um aumento da actividade da PLD em culturas primárias 
de neurónios e que esse efeito estimulatório não ocorre após a delecção genética da PLD2.  
A Aβ perde o seu efeito suppressor de potenciação de longo termo em fatias de hipocampo de 
ratinhos Pld2--/-, sugerindo que a PLD2 é necessária para o efeito sinaptotóxico deste péptido. A 
actividade da PLD in vivo, medida através da detecção dos níveis de fosfatidiletanol, por espectrometria 
de massa (MS) após injecção de etanol, também está aumentada no cérebro de um modelo 
transgénico de AD (SwAPP). Para além disso a ablação da Pld2 recupera os défices de memória e leva 
a uma protecção sináptica em ratinhos SwAPP, apesar dos altos níveis de Aβ. Análise de lípidos por 
MS de cérebros de ratinhos mutantes para a Pld2 na presença ou ausência do transgene SwAPP 
revela haver uma intensa intraregulação nas espécies de PA. Esta análise lipídica mostra uma 
especificidade e plasticidade no modo como o metabolismo do PA está alterado, com uma marcada 
elevação nos cérebros SwAPP de uma espécie de PA previamente ligado a processos 
neurodegenerativos. Em suma, os nossos resultados apontam para espécies específicas de PA como 
moduladores da patogénese da AD e identificam a PLD2 como um novo alvo potencial terapêutico. 
Além disso, expandimos a nossa análise por MS para outros lípidos, para além de PA. Observámos 
que a sobreexpressão do transgene SwAPP leva a um aumento do gangliosídeo, GM3. A ablação 
genética de Pld2 leva a um decréscimo de GM3 nos animais não-transgénicos e a uma renormalização 
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dos valores nos animais SwAPP. Em conclusão, esta análise lipidómica revelou ligações mecanísticas 
interessantes reguladas pela PLD2, no contexto da AD. 
  
x 
 
  
xi 
 
CONTENTS 
1.Introduction 1 
     1.1. Alzheimer‟s Disease 3 
     1.2 Phospholipids and Alzheimer‟s Disease 5 
     1.3. Phospholipase D – Structure, Function and Localization 6 
     1.4. Lipids and Lipidomics 9 
     1.5. Phospholipase D and Alzheimer‟s disease 9 
     1.6  Aims 12 
2. Experimental work 19 
     2.1. Phospholipase D2 ablation ameliorates Alzheimer‟s disease-linked synaptic 
            dysfunction and cognitive deficits 
21 
     2.2. The impact of phospholipase D2 ablation in the forebrain of Tg2576 mice –  
            mechanistic insights from a lipidomic study 
65 
3. Discussion, Conclusions and Future perspectives 87 
4. Annexes 101 
    4.1  Phospholipase D in brain function and Alzheimer‟s disease (review) 103 
xii 
 
Abbreviations 
 
α7nAchR - alpha7 nicotinic acetylcholine receptor  
Aβ - amyloid β-peptide  
AD - Alzheimer‟s disease  
AICD - APP intracellular COOH-terminal domain  
AMPAR - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
APLP2 - APP-like-protein 2 
APP - β-amyloid precursor protein 
BACE1 - Beta-site APP cleavage enzyme 1  
BST - Basal synaptic transmission 
CDK5 - cyclin-dependent kinase 5  
Cer - ceramides 
cPLA2 - cytosolic phospholipase A2 
CTF - COOH-terminal fragment  
DAG - diacylglycerol 
ERK - extracellular signal-regulated kinase 
fEPSPs - field-excitatory post-synaptic potentials  
FPRL1 - formyl-peptide-receptor-like 1 
Glu-Cer - glucosyl-ceramide 
GSK3 - glygogen synthase kinase 3 
KO - knock-out 
LPA - lysophosphatidic acid 
LTP - long-term potentiation 
LC - Liquid chromatography 
MAPT - microtubule-associated protein tau  
MARK - microtubule-affinity-regulating kinase  
MEFs - mouse embryonic fibroblasts 
MS - mass spectrometry 
mTOR – mammalian target of rapamycin 
NFTs - neurofibrillary tangles  
NMDAR - N-methyl D-aspartate receptor 
xiii 
 
PA - phosphatidic acid  
PC - phosphatidylcholine  
PE - phosphatidylethanolamine 
PG - phosphatidylglycerol 
PH - pleckstrin homology 
PI - phosphatidylinositol 
PI(4,5)P2 - phosphoinositol-4,5-bisphosphate  
PLA2 - phospholipase A2  
PLC - phospholipase C  
PLD - phospholipase D  
PrP - prion protein 
PS - phosphatidylserine 
PS1 - presenilin 1  
PS2 - presenilin 2  
PSD95 – post synaptic density 95 
PtdEtOH - phosphatidylethanol 
PtdBut - phosphatidylbutanol 
PX - phox  
SM - sphingomyelin 
SwAPP – Swedish APP 
WT - wild type 
  
xiv 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 1  
____________________________________________________________________ 
Introduction  
2 
 
  
3 
 
Introduction 
 
1.1. Alzheimer’s Disease 
Alzheimer‟s disease (AD) is a neurodegenerative disease characterized clinically by progressive 
memory deficits, impaired cognitive function, altered behavior, and a decline in language function 
(Tanzi and Bertram 2005; Haass and Selkoe 2007; Querfurth and LaFerla 2010). The brain of AD 
patients displays cortical atrophy, loss of neurons and synapses, and typically presents at the 
anatomopathological analysis with plaques and neurofibrillary tangles (NFTs). While senile plaques are 
largely composed of aggregated amyloid β-peptide (Aβ) (Tanzi and Bertram 2005; Haass and Selkoe 
2007), tangles consist of pairs of ~10 nm filaments wound into helices, also called paired helical 
filaments, and contain hyperphosphorylated forms of the microtubule-associated protein tau (MAPT). 
Growing evidence indicates that there is crosstalk between Aβ and tau pathogenesis (Small and Duff 
2008). Genetic studies of families with AD have identified several genes, β-amyloid precursor protein 
(APP), presenilin 1 (PS1) and presenilin 2 (PS2), that are important in the pathogenesis of AD. APP is 
the precursor protein that after cleavage gives rise to Aβ, and the presenilins have been identified as 
components of the -secretase complex, which, alongside the β-secretase, are responsible for the 
generation of Aβ (Tanzi and Bertram 2005; Haass and Selkoe 2007) (figure 1). 
 Aβ is derived from the sequential cleavage of type I transmembrane protein APP by 
membrane-bound proteases, β- and -secretase (Selkoe, Podlisny et al. 1988; Landman and Kim 
2004; Wilquet and De Strooper 2004). Beta-site APP cleavage enzyme 1 (BACE1) has been identified 
as the major β-secretase activity that mediates the first cleavage of APP in the β-amyloidogenic 
pathway (Sinha and Lieberburg 1999; Haass 2004). BACE1-mediated cleavage leads to the release of 
the APP ectodomain sAPPβ into the extracellular space. The remaining COOH-terminal fragment (CTF) 
undergoes subsequent cleavage by -secretase to release Aβ and the APP intracellular COOH-terminal 
domain (AICD). The presenilins have been proposed to be the major catalytic component of the -
secretase complex, whose sequential intramembrane cleavage of APP produces a spectrum of Aβ 
peptides varying in length by a few amino acids at the COOH-terminus (Haass 2004; Landman and 
Kim 2004). The majority of Aβ normally ends at amino acid 40 (Aβ40), but the 42-amino acid variant 
(Aβ42) is more amyloidogenic, and has been hypothesized to nucleate senile plaque formation (Haass 
2004; Landman and Kim 2004; Haass and Selkoe 2007). In the past few years it has been shown that 
soluble oligomeric Aβ40/42 in various assembly states better correlate with synaptic malfunction and 
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cognitive impairment than neuritic plaques in vivo, consistent with mounting evidence that oligomeric 
Aβ is significantly synaptotoxic (Haass and Selkoe 2007) (figure 1). 
 As mentioned above, a number of links exist between Aβ and tau pathologies. Importantly, in 
an AD mouse model associated with a significant Aβ burden, the genetic ablation of tau was 
neuroprotective in the context of Aβ-induced deficits (Roberson, Scearce-Levie et al. 2007) (Ittner, Ke et 
al. 2010), supporting an intimate crosstalk between Aβ and tau. Even though, it is not clear whether 
the precise reasons for the protective role(s) of tau ablation are related directly to tau‟s pathogenic 
potential, it has been shown that the ablation of tau decreases the excitotoxic potential induced by Aβ, 
by decreasing the NMDAR/PSD95 interaction in a Fyn-dependent way (Ittner, Ke et al. 2010). Overall, 
this relationship between the two major pathogenic AD hallmarks remains under intense study (Small 
and Duff 2008). Nevertheless, development of an improved understanding of tau-related pathology may 
inform not only our knowledge of Aβ-related dysfunction in AD but the illness as a whole. While no 
familial genetic studies have shown a direct cause effect for tau mutations in AD, mutations in the 
MAPT gene were shown to cause a distinct neurodegenerative disorder, frontal temporal dementia, 
which is not associated with neuritic plaques. There is a single MAPT gene, which, through alternative 
splicing, can lead to the expression of six different isoforms in the human brain. MAP tau has a well-
established known function of stabilizing microtubules. The microtubule-binding capacity of tau is 
known to be regulated by post-translational modifications. The most well established process is 
phosphorylation, mediated by a number of kinases including glygogen synthase kinase 3 (GSK3), 
cyclin-dependent kinase 5 (CDK5) and microtubule-affinity-regulating kinase (MARK). The formation of 
NFTs is thought to be a sequential process that starts with impaired tau phosphorylation, detachment 
of tau from microtubules, accumulation of misfolded tau, tau aggregation in pretangles, formation of 
paired helical filaments and finally NFTs (Ballatore, Lee et al. 2007).  
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Figure 1. After Aβ is produced from the sequential cleavage of APP, if not cleared, it can be 
aggregated into oligomers, fibrils and plaques. It has been proposed that the Aβ oligomers are toxic 
species that can lead to neuronal dysfunction. PHF – paired helical filaments, AD – Alzheimer Disease. 
 
1.2. Phospholipids and Alzheimer’s Disease 
Lipid-mediated signaling regulates a plethora of physiological processes, including multiple aspects of 
brain function. Dysregulation of lipid pathways has been involved in a growing number of 
neurodegenerative disorders. While much attention has been given to the sterol link to AD (Puglielli, 
Tanzi et al. 2003), growing evidence, suggests that other classes of lipids, such as phospholipids, 
either mediate or modulate key pathological processes associated with AD (Landman, Jeong et al. 
2006; Berman, Dall'Armi et al. 2008; Sanchez-Mejia, Newman et al. 2008).  
 The interaction of both tau and Aβ with cellular and artificial membranes has been extensively 
investigated. Given direct binding of tau to membrane phospholipids, it was hypothesized that this 
interaction may be relevant for the physiological function of tau as well as AD pathogenesis (Baudier 
and Cole 1987). Similarly, Aβ can directly alter artificial lipid bilayers by forming pores that are 
permeable to various ions (Arispe, Rojas et al. 1993). More recently, after the discovery of the 
synaptotoxic properties of soluble Aβ oligomers, studies showed that these oligomers destabilize 
membranes and trigger Ca2+ influxes through unknown mechanisms (Demuro, Mina et al. 2005). In 
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part reflecting the pathophysiological relevance of oligomer-induced Ca2+ dyshomeostasis, acute and 
chronic treatments of neurons with soluble oligomers of Aβ were shown to disrupt the metabolism of 
phosphoinositol-4,5-bisphosphate [PI(4,5)P2] in a phenomenon requiring both extracellular Ca2+and PLC 
activity (Berman, Dall'Armi et al. 2008). Similarly, a recent study showed that dysregulation of the 
group IV A phospholipase A2 pathway mediates some aspects of synaptic and neurobehavioral 
dysfunction in a mouse model of AD (Sanchez-Mejia, Newman et al. 2008). These two studies provide 
further support to a prior hypothesis maintaining that phospholipases are highly dysregulated in AD 
(Farooqui, Rapoport et al. 1997).  
 Given the body of evidence presented above demonstrating the importance of phospholipids 
and AD, development of an improved understanding of phospholipid signaling is essential. Increasing 
evidence (see below) has pointed to one enzyme family especially in regulating biosynthesis and 
metabolism of phospholipids: phospholipase D (PLD). We conducted this work addressing the 
hypothesis that in AD there is an overall dysfunction of phospholipases. 
 
1.3. Phospholipase D – Structure, Function and Localization 
In the last two decades the purification (Wang, Dyer et al. 1993) and cloning (Wang, Xu et al. 1994) of 
PLD in plants boosted the follow-up studies in mammals with the cloning of two PLD isozymes, PLD1 
(Hammond, Altshuller et al. 1995) and PLD2 (Colley, Sung et al. 1997; Kodaki and Yamashita 1997). 
In mammals there are three isozymes of PLD: PLD1, PLD2 and the recently-identified mitochondrion-
associated mitoPLD (Jenkins and Frohman 2005; Choi, Huang et al. 2006; Donaldson 2009). The 
majority of studies have so far focused on PLD1 and PLD2 (figure 2A), which share: (i) two HxKxxxxD 
(HKD) motifs that are essential for catalysis; (ii) a phox (PX) consensus sequence and (iii) a pleckstrin 
homology (PH) domain, which are phosphoinositide-binding modules that are required for proper 
targeting of PLD; and (iv) a PIP2-binding site, which is fundamental for the enzymatic activity. However, 
PLD1 differs from PLD2 by the presence of a loop region, which has been proposed to function as a 
negative regulatory element for catalysis (figure 2A) (Jenkins and Frohman 2005). In the presence of 
water, both PLD1 and -2 hydrolyze phosphatidylcholine (PC) to generate phosphatidic acid (PA) and 
free choline. However in the presence of primary alcohols, such as ethanol and 1-butanol, PLD 
preferentially (1000-fold) uses these nucleophiles over water for the transphosphatidylation reaction, 
thus leading to the formation of non-naturally occurring phospholipids, phosphatidylethanol (PtdEtOH) 
or phosphatidylbutanol (PtdBut), respectively (Gustavsson 1995) (figure 2B). This atypical property of 
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the enzyme has been exploited in a myriad of studies either to block the production of bioactive lipid PA 
or to measure PLD activity in intact cells or tissues. 
 PA has unique bioactive properties and can modify both the physical and signalling properties 
of lipid bilayers. Structurally, it is composed of a three-carbon glycerol backbone, two fatty acid chains 
and a small phosphate headgroup, thus referred to as a „cone shape‟ lipid (i.e., a lipid with a small 
head groups relative to a large hydrophobic domain) (Jenkins and Frohman 2005; Cazzolli, Shemon et 
al. 2006). This property not only confers PA a higher affinity for negative curvature within lipid bilayers, 
but it also reduces the energy barrier for bending membranes, thus acting as a fusogenic lipid. 
Somewhat reminiscent of phosphoinositides, PA also plays an important role at the membrane-cytosol 
interface through a direct interaction with effector proteins, such as PIP kinases, mTOR, SNARE 
proteins and sphingosine kinase (Stace and Ktistakis 2006). However, unlike a variety of 
phosphoinositide-binding modules (e.g., pleckstrin homology or FYVE domains), PA-binding 
(poly)peptides generally do not consist of well defined three dimensional folds, but instead involve basic 
residues in unstructured parts of effector proteins. Additionally, PA can be metabolized to other lipids 
with potent bioactivity. For instance, PA can be converted to diacylglycerol (DAG) by PA phosphatases 
(Sciorra and Morris 2002; Reue 2009) and to lysophosphatidic acid (LPA), which has an inverted cone 
shape and thus prefers positive curvature. Finally, PA can serve as a precursor for other lipids in the 
biosynthetic pathway, where it is consumed for the generation of lipids such as PI via the CDP-DAG 
pathway. It should be noted that PLD is not the only source of PA, as it can be produced by DAG 
kinases, LPA acid acyltransferase, mitoPLD and other enzymes in the biosynthetic pathway (Choi, 
Huang et al. 2006; Haucke and Di Paolo 2007) (figure 2C). However, the fatty acyl composition of PA 
pools varies, depending on the specific pathways mediating its production. For example, PLD-derived 
PA species harbor mainly saturated or monounsaturated fatty acids, rapidly giving rise to a pool of DAG 
with the same properties (i.e., a cone shape), although the negative charge of PA may confer distinct 
properties and allow for the binding to a different set of effector proteins compared to DAG. In contrast, 
the pool of DAG resulting from PI(4,5)P2 cleavage by PLC predominantly harbors polyunsaturated fatty 
acids, likely achieving different physiological functions (Pettitt, Martin et al. 1997; Pettitt, McDermott et 
al. 2001). 
 While PLD1 localizes to the Golgi complex, secretory granules and endosomes, PLD2 is 
concentrated at the plasma membrane, with smaller pools present in the Golgi apparatus, caveolae 
and in endosomes (Freyberg, Sweeney et al. 2001; Freyberg, Bourgoin et al. 2002; Freyberg, 
Siddhanta et al. 2003; Bader and Vitale 2009). In part consistent with their subcellular localization, 
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PLD1 has been implicated in the budding and fusion of trans-Golgi–derived secretory vesicles, whereas 
PLD2 mediates the internalization and recycling of a variety of receptors. Importantly, PLD1 
translocates to the plasma membrane upon various stimuli and follows the endosomal internalization 
route (Jenkins and Frohman 2005; Roth 2008; Donaldson 2009). 
  
 
 
Figure 3. PLD structure, PA metabolism and reactions catalyzed by PLD. (a) Structure of PLD 
isozymes. Structurally, the two isozymes differ by the presence of a loop domain in the PLD1 isozyme. 
(b) PA metabolism. Besides the PLD source, PA can be generated from other sources and further 
metabolized as represented in the figure. The dashed arrow represents the biosynthetic pathway. The 
enzymes catalyzing the respective reactions are shown in red. (c) PLD activity. In the presence of 
water, PLD produces PA. In the presence of primary alcohols, such as ethanol, PLD has a 1000-fold 
higher affinity for primary alcohols as nucleophiles, leading to a preferential generation of 
phosphatidylethanol (PEtOH). PLD, Phospholipase D; PC, phosphatydilcholine; PA, phosphatidic acid; 
LPA, lyso-PA; DAG, diacylglycerol; CDP-DAG, cytidine diphosphate-DAG; PLA2, phospholipase A2; 
LPAAT, LPA acyltransferase; PAP, PA phosphatase; DGK, DAG kinase; CDS, CDP-DAG synthase; 
mitoPLD, mito-phospholipase D. (adapted from (Oliveira and Di Paolo 2010)) 
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1.4. Lipids and Lipidomics 
Although genomic and proteomic studies are nowadays commonly used in research, the field of 
lipidomics is only now having increased attention, which was in part allowed by technological advances 
in liquid chromatography and mass spectrometry (Wenk 2005). Lipidomics studies allow the 
characterization of a vast array of lipid species from a given sample. For instance, as for genomics and 
proteomics, lipidomics studies allow the identification of potential pathways, in this case involving 
lipids, which are dysregulated in a certain disease, such as neurodegenerative disorders (Wenk 2005). 
In the case of AD, this approach is starting to be employed to identify new possible targets, using 
human and mouse model brain samples (Sanchez-Mejia, Newman et al. 2008) (Han 2010). 
Lipidomics can also be used to understand mechanistically the lipid alterations of a given alteration. 
 
1.5. Phospholipase D and Alzheimer’s disease 
Previously, some studies have addressed the link between PLD and AD. Kanfer et al using PEtOH 
production as a read-out for PLD activity in ethanol-incubated brain homogenates, found an increase in 
PLD activity in AD brain extracts relative to those from control subjects (Kanfer, Singh et al. 1996). 
Also, using cell culture models the impact of APP overexpression and extracellular Aβ applications on 
PLD activity was assessed. Overexpression of the neuronal isoform of human wild type APP in P19 
mouse embryonic cells caused an increase in PLD activity (Lee, Oh et al. 2001). Aβ application 
experiments were used as well with various peptide preparation types. In LA-N-2 cells, a neuroblastoma 
cell line, an increase in PLD activity was observed after incubating cells with Aβ25-35, a peptide 
sequence whose pathophysiological significance has been questioned (Singh, Mccartney et al. 1995). 
Additionally, the same group showed that indomethacin (a non-steroid anti-inflammatory drug), 
nordihydroguaiaretic acid (an anti-oxidant drug) and nicotine inhibited the increase in PLD activity 
produced by Aβ25-35 applications (Singh, Sorrentino et al. 1997; Singh, Sorrentino et al. 1998). 
Furthermore, alanine substitution for the amino acids on the position 29-34 of Aβ25-35 prevented the 
peptide from having an effect on PLD activity (Singh, Sato et al. 1997). Finally, pre-treatment with 
Aβ25-35 desensitized the cells, which did not exhibit a PLD activity increase in response to a new 
Aβ25-35 treatment, thus prompting the authors to suggest that Aβ25-35 might mediate its effects on 
PLD upon receptor binding (Singh, Sorrentino et al. 1998). Aβ1-40 also produced an increase in PLD 
activity in rat hippocampal primary cultures, but this effect was seen with high concentrations of Aβ 
aged at 37ºC (likely reflecting a requirement for some aggregated state of Aβ for this phenomenon to 
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occur) (Cox and Cohen 1997). The increase in PLD activity induced by Aβ correlated with increased 
release of cytosolic protein lactate dehydrogenase, suggesting it is associated with Aβ-induced toxicity 
(Cox and Cohen 1997). Besides neurons, Aβ1-42 used in the low micromolar range caused an 
increase in PLD activity in astrocytes and microglia in a process dependent upon formyl-peptide-
receptor-like 1 (FPRL1). Specifically, Aβ1-42 was internalized alongside the FPRL1 receptor and 
stimulated a downstream signaling pathway involving the phosphorylation of extracellular signal-
regulated kinase (ERK). Because both Aβ1-42 internalization and FPRL1-mediated signaling were 
abrogated by a primary alcohol, a role for PLD in this process was proposed (Brandenburg, Konrad et 
al. 2008). 
 While the above studies addressed the effects of Aβ on PLD, there were other groups that 
addressed the role of PLD on the trafficking of APP and its cleavage machinery. Because Aβ originates 
from the sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases, tremendous 
effort has been put into attempting to understand the molecular mechanisms regulating the subcellular 
localization and intracellular sorting of APP and its cleaving enzymes, all of which are transmembrane 
proteins or protein complexes. Generally, an increasingly popular hypothesis in the field is that 
perturbation of the trafficking of APP, BACE1 and γ-secretase complex [including its catalytic 
components, presenilins] may profoundly affect amyloidogenesis and thus impact AD pathogenesis 
(Small and Gandy 2006). While the bulk of the studies addressing the relationship between the γ-
secretase complex and APP focus on the APP processing, some evidence indicates that presenilin can 
also regulate the trafficking of APP independently of its catalytic activity. Specifically, TGN-derived 
secretory vesicles produced from PS1-deficient cells contain higher levels of APP, thus resulting in 
increased cell surface delivery of APP. The converse phenomenon was observed in cells expressing an 
FAD mutant version of PS1 (i.e., ΔE9), suggesting that these findings may be relevant for the 
pathogenesis of AD (Cai, Leem et al. 2003). Collectively, these results converged onto a transport 
pathway involving APP, PS and PLD1, although evidence for a bona fide crosstalk between these three 
molecules in the context of TGN-to-plasmalemma traffic emerged in subsequent studies.  
 Accordingly, PLD1 overexpression was shown to promote the formation of APP-containing 
secretory vesicles from TGN, thus mimicking the effect of PSEN1 nullizygosity (Cai, Zhong et al. 2006). 
However, primary alcohols failed to rescue this phenotype in PS1 knockout cells, suggesting that the 
increased biogenesis of APP-containing vesicles observed in PS1-deficient cells is PLD-independent. 
While these data suggested that WT PS1 and PLD1 may regulate the traffic of APP through 
independent pathways, there is a clear functional link between these two proteins in the FAD mutant 
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background (at least, for the PS1ΔE9 mutant). For instance, a subcellular fractionation experiment 
showed that expression of FAD PS1ΔE9 mutant in cells leads to an enrichment of PLD1 in the 
Golgi/TGN fraction at the expense of lighter fractions (which may in part represent endosomal 
structures) and that this redistribution was concomitant with a decrease in total PLD activity (Cai, 
Zhong et al. 2006). Importantly, overexpression of catalytically-active PLD1 (but not the lipase-dead 
mutant) was found to rescue the defect in the budding of APP-containing vesicles from the TGN as well 
in the cell surface delivery of APP induced by the PS1 ΔE9 (Cai, Zhong et al. 2006). Whether PLD1 
interacts with APP or not is a matter of debate as conflicting data were obtained in independent studies 
(Jin, Kim et al. 2006; Liu, Zhang et al. 2009). 
 While the aforementioned study highlights the effects of PLD1 on APP trafficking, Cai et al. also 
addressed the role of PLD1 in amyloidogenesis. First, it was shown that PLD1 (but not PLD2) physically 
interacts with the cytoplasmic loop region of PS1 and that through this binding PS1 mediates the 
recruitment of PLD1 to the Golgi complex. Furthermore, in N2a cells expressing the PS1 mutant ΔE9, 
overexpression of PLD1 decreased the levels of Aβ, whereas silencing PLD1 and expression of a lipase-
dead PLD1 mutant produced the converse effect. Interestingly, co-precipitation experiments showed 
that PLD1 regulates the assembly of the γ-secretase complex through a direct effect on PS1 (but not 
the other components of the complex: Pen-2, nicastrin and APH1), although this phenomenon appears 
to be independent of the lipase activity of PLD1 (Cai, Netzer et al. 2006). 
 Since PLD1 regulates the traffic of APP and that APP, in turn, may affect the transport of PS1, 
it was hypothesized that PLD1 could regulate the trafficking of PS1 indirectly, through APP. However, 
recently published evidence has suggested that PLD1 positively regulates the delivery of PS1 to the cell 
surface in an APP-independent fashion (Liu, Zhang et al. 2009). Indeed, analysis of PS1 localization in 
mouse embryonic fibroblasts (MEFs) lacking both APP and its related family member APP-like-protein 2 
(APLP2) (APP dKO) showed increased cell surface delivery of PS1. This phenomenon was mimicked by 
the overexpression of catalytically-active PLD1, but it also occurred in APPdKO cells, thus suggesting 
that it is independent of an effect of PLD1 on APP transport (Liu, Zhang et al. 2009).  
 In summary, there appears to be a significant crosstalk between PLD1, APP and PS1 with 
important implications for amyloidogenesis. However, it is unclear whether this crosstalk also occurs in 
vivo, which should be best addressed with genetic models. Importantly, PLD1 and PLD2 are likely to 
play distinct roles in AD pathogenesis, likely reflecting their differential subcellular localization, 
expression levels/profile, and regulation as well as their ability to control different aspects in the biology 
of the key proteins involved in AD. 
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1.6. Aims 
The main goal of this proposal is to understand the role of PLD2 in the pathogenesis of AD. The 
specific aims of this project are: 
1. To characterize the effects of Aβ on the PLD pathway. 
2. To test the effects of PLD2 ablation in an AD mouse model. 
3. To investigate the role of PLD2 in APP processing and Aβ generation. 
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Abstract 
Growing evidence implicates aberrant lipid signaling in Alzheimer‟s disease (AD). While phospholipases 
A2 and C have been recently shown to mediate key actions of amyloid β-peptide (Aβ) through a 
dysregulation of arachidonic acid and phosphatidylinositol-4,5-bisphosphate metabolism, respectively, 
the role of phospholipase D (PLD) has so far remained elusive. PLD produces phosphatidic acid (PA), a 
bioactive lipid involved in multiple aspects of cell physiology, including signaling and membrane 
trafficking processes. Here we show that oligomeric Aβ enhances PLD activity in cultured neurons and 
that this stimulatory effect does not occur upon ablation of PLD2 via gene targeting. Aβ fails to 
suppress long-term potentiation in PLD2-deficient hippocampal slices, suggesting that PLD2 is required 
for the synaptotoxic action of this peptide. In vivo PLD activity, as assessed by detection of 
phosphatidylethanol levels using mass spectrometry (MS) following ethanol injection, is also increased 
in the brain of a transgenic mouse model of AD (SwAPP). Furthermore, Pld2 ablation rescues memory 
deficits and confers synaptic protection in SwAPP mice despite a significant Aβ load. MS-based lipid 
analysis of Pld2 mutant brains in the presence or absence of the SwAPP transgene unmasks striking 
crosstalks between different PA species. This lipid analysis shows an exquisite acyl chain specificity and 
plasticity in the perturbation of PA metabolism, with the notable elevation in SwAPP brains of a pool of 
PA previously linked to degeneration. Collectively, our results point to specific molecular species of PA 
as key modulators of AD pathogenesis and identify PLD2 as a novel potential target for therapeutics. 
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Introduction 
Cerebral accumulation of amyloid beta (Aβ) is believed to mediate many aspects of Alzheimer‟s 
disease (AD)-associated pathogenesis. Aβ is produced by the sequential cleavage of the amyloid 
precursor protein (APP) by β- and γ-secretases. While Aβ40 is the predominant cleavage product, the 
longer peptide Aβ42 is more cytotoxic and aggregate-prone (Small and Gandy, 2006; Haass and 
Selkoe, 2007; Vassar et al., 2009; De Strooper et al., 2010). Although AD brains typically harbor senile 
plaques that consist of insoluble aggregates of Aβ, different assemblies of Aβ, including fibrils as well 
as soluble dimers, trimers and dodecamers, may differentially contribute to AD pathogenesis at various 
stages of this disorder (Lambert et al., 1998; Walsh et al., 2002; Haass and Selkoe, 2007). 
Importantly, elevation of soluble Aβ oligomers strongly correlates with cognitive decline, consistent with 
the synaptotoxic properties exhibited by these peptides in various systems (Haass and Selkoe, 2007). 
For instance, Aβ oligomers disrupt synaptic plasticity, the trafficking of glutamate receptors, dendritic 
spine dynamics and Ca2+ homeostasis (Demuro et al., 2005; Snyder et al., 2005; Hsieh et al., 2006; 
Haass and Selkoe, 2007; Shankar et al., 2007; Green and LaFerla, 2008). Importantly, recent work 
has suggested that Aβ oligomers may exert their effects upon binding to the cellular prion protein on 
the neuronal membranes (Lauren et al., 2009).  
 
 Mounting evidence indicates that Aβ perturbs the metabolism of intracellular signaling lipids and 
that this phenomenon contributes to the pathogenic actions of this peptide (Hartmann et al., 2007). In 
particular, work from our laboratory has shown that Aβ42 oligomers promote the hydrolysis of a major 
regulatory lipid phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] through a stimulation of the 
phospholipase C (PLC) pathway and that preventing PI(4,5)P2 deficiency protects against the synapse-
impairing actions of Aβ (Berman et al., 2008). Similarly, Aβ stimulates cytosolic phospholipase A2 
(cPLA2), thereby enhancing the levels of arachidonic acid, and reduction of the relevant PLA2 isoform 
by genetic means confers protection against the peptide (Sanchez-Mejia et al., 2008). Collectively, 
these studies suggest that phospholipases may be primary mediators of Aβ‟s action.  
 
 Phospholipase D (PLD), another family of phospholipases, has also been implicated in AD 
pathogenesis (Singh et al., 1995; Cai et al., 2006b; Brandenburg et al., 2008; Liu et al., 2009). PLD1 
and PLD2, which are differentially localized in cells, hydrolyze phosphatidylcholine (PC) into choline and 
a bioactive lipid, phosphatidic acid (PA) (Freyberg et al., 2003; Jenkins and Frohman, 2005; Roth, 
2008; Donaldson, 2009). This lipid regulates membrane dynamics and signaling processes through its 
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intrinsic physical properties (i.e., „cone shape‟) and interaction with effector proteins (Jenkins and 
Frohman, 2005; Stace and Ktistakis, 2006; Haucke and Di Paolo, 2007; Roth, 2008; Raghu et al., 
2009a). In the present study, we tested the involvement of PLD2 in AD pathogenesis and more 
specifically, in the synaptotoxic action of Aβ oligomers. We reasoned that PLD2 was likely to mediate 
the previously-reported increase in total PLD activity induced by Aβ, based on the predominant 
localization of this isozyme at the cell surface (Du et al., 2004), a major site of action for Aβ. We show 
that ablating PLD2 through genetic means blocks the synaptotoxic action of Aβ42 oligomers and 
rescues memory deficits in a transgenic model of AD independently of brain Aβ levels.  
  
Materials and Methods 
Cell culture. PC12 cells were maintained in Dulbecco‟s modified Eagle‟s medium with sodium pyruvate 
(Invitrogen) supplemented with 5% fetal bovine serum, 10% horse serum, glutamine (4 mM), penicillin 
(200 units/mL), streptomycin (200 μg/mL); cells were maintained at 37°C in 5% CO2. Twenty-four 
hours before transfection, PC12 cells were plated (at 50% confluence) on coverslips pre-coated with 
polylysine (20g/mL) for 1 hr at 37°C. Transfections of GFP-mouse PLD2 construct (kind gift of 
Michael Frohman, SUNY Stony Brook, New York), which was previously described (Du et al., 2004), 
were obtained using Lipofectamine 2000 (Invitrogen). Primary cultures from cortical neurons were 
generated from newborn wild-type mice. Briefly, cortices were dissected out, trypsinized for 30min, and 
then cortical cells dissociated with a Pasteur pipette and plated on poly-ornithine-coated 10mm dishes 
at a density of 25,000 cells/cm2 in Neurobasal-A medium containing 1mM kynurenic acid to reduce 
enhanced synaptic transmission due to the high densi
typically performed after 15 DIV, with 200nM concentration and with time duration of 4hours for 
primary neuronal cultures and 5, 30 and 60 minutes in PC12 cells. Ionomycin was used with 2μM 
concentration for 30 minutes. 
 
Peptide preparation. A oligomers were prepared as described previously (Dahlgren et al., 2002). 
Synthetic A (1-42) was purchased from American Peptide (Sunnyvale, CA) and stored at -20ºC. The 
vial containing the peptide was allowed to equilibrate to room temperature for at least 30 min before 
resuspension. In a fume hood the peptide was diluted to 1mM in 1,1,1,3,3,3-Hexafluoro-2-propanol 
(HFIP) by pipette mixing and immediately aliquoted in polypropylene microcentrifuge tubes. The 
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solution was vortexed briefly and allowed to evaporate in the fume hood for 2 hours. The resulting 
peptide films were dried in a Speed Vac for 10 minutes at 800xg and stored at -20ºC. Prior to use, the 
peptide film was resuspended to 1mM in dimethyl sulfoxide (DMSO) by pipette mixing followed by bath 
sonication for 10 minutes. The solution was aliquoted in polypropylene microcentrifuge tubes and 
stored at -20ºC. The peptide was used within two weeks of dilution in DMSO. Oligomeric forming 
conditions: the 1mM DMSO solution was diluted to 100 M in cold PBS, vortexed for 30 seconds, and 
incubated overnight at 4ºC (minimum incubation of 12 hours). Immediately before use, the A-PBS 
solution was further diluted in culture media to the required final concentration and vortexed briefly. 
This preparation contains a mixture of monomers, trimers and tetramers as well as traces of dimers 
and high molecular weight oligomers, as shown previously (Berman et al., 2008).  
 
Mouse strains and breeding strategy. The genetic background of the Pld2 mice is mixed (C57BL/6-
129svj). Pld2–/– females were crossed with Tg2576 males (Taconic- mixed background C57BL/6-
SJL/N), which express human APP carrying the double mutation K670N and M671L found in a 
Swedish family with early onset of Alzheimer‟s disease, under the regulation of the hamster prion 
protein promoter (Hsiao et al., 1996). From the F1 hybrid generation we used as breeders Pld2+/–/no tg 
females and Pld2+/–/SwAPP males. For all our animal studies we used littermate mice (or in some 
cases, mice sharing at least one parent) derived from the F2 generation. The survival rate of adult mice 
was >90% for all genotypes within the first 12 months of age (and thus the impact of Pld2 deletion on 
the survival of SwAPP mice was not investigated further). 
 
ELISA analysis. Brains were homogenized in 10 volumes of 50 mM Tris–HCl buffer, pH 7.6, containing 
250 mM sucrose and protease inhibitor cocktail (Sigma, St. Louis, MO). Soluble and total Aβ were 
extracted in 0.4% diethylamine (DEA) and 70% formic acid, respectively, as previously described 
(Schmidt et al., 2005). Levels of full-length Aβ 1–40 and 1–42 were quantified using antibodies 
donated by Centocor according to previously-published ELISA procedures (Schmidt et al., 2005). 
Murine Aβ was measured according to a previously-published procedure (Burns et al., 2003). 
 
Western Blot analysis. The DEA fraction of brain extracts from Pld2/SwAPP mutant mice was 
immunoblotted using a rabbit polyclonal antibody to the COOH terminus of PLD (kind gift of Dr. Sung 
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Ho Ryu, Pohang University of Science and Technology), rabbit polyclonal antibody to PLD1 (Cell 
Signaling), mouse monoclonal antibody to APP (6E10, Covance), mouse monoclonal antibody to 
PSD95 (6G6-1C9, Abcam), rabbit polyclonal Synaptophysin (G95, kind gift of Dr. Pietro De Camilli, Yale 
University) and a mouse monoclonal antibody to -tubulin (B-5-1-2, Sigma). Quantification was 
performed using ImageJ software. 
 
PLD activity. Ten day-old neurons were incubated with [3H] palmitic acid (2 µCi/ml) for approximately 5 
days to label cellular phospholipids. Following treatments with vehicle or oAβ42, neurons were 
incubated in the presence of 0.3% butanol for 30 min, which leads to the production and accumulation 
of [3H]phosphatidylbutanol via a PLD-specific transphosphatidylation reaction. Radiolabeled lipids, 
including phosphatidylbutanol, were isolated by solvent extraction and separated by thin layer 
chromatography. The total amount of [3H]phosphatidylbutanol is expressed as a percentage of total [3H]-
labeled lipids (Morris et al., 1997). 
 
Confocal microscopy. Analysis of GFP-PLD2 internalization. Twenty-four hours after transfection with a 
plasmid encoding GFP-PLD2, PC12 cells were incubated with vehicle or 200 nM oA42 for 5, 30 and 
60 minutes. Other treatments included 2 μM ionomycin (Sigma-Aldrich), 2 mM EGTA (company), 250 
nM U-73122 (Calbiochem) and 20 μM AACOCF3 (Calbiochem) for 30 min, as indicated in the figure 
legend. Cells were then washed in phosphate buffer and fixed with 4% paraformaldehyde. Confocal z-
stack images (0.5μm) of PC12 were obtained using Nikon EZ-C1.2.30 confocal microscope and an oil 
immersion objective (100x). Quantification of GFP intensity was calculated using the ImageJ software: 
for each cell in a given image, a line intensity profile across the cell was obtained. The relative decrease 
in plasma membrane localization was calculated as the ratio between the plasma membrane 
fluorescence intensity and the average cytosolic fluorescence intensity, as previously described 
(Berman et al., 2008). 
 
Electrophysiology. Transverse hippocampal slices (400 μm) were cut with a tissue chopper (EMS, PA) 
and maintained in an interface chamber at 29 °C for 90 min prior to recording, as previously reported 
(Puzzo et al., 2005). CA1 field-excitatory post-synaptic potentials (fEPSPs) were recorded by placing 
both the stimulating and the recording electrodes in CA1 stratum radiatum. Basal synaptic 
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transmission (BST) was evaluated either by plotting the stimulus voltages (V) against slopes of fEPSP, 
or by plotting the peak amplitude of the fiber volley against the slope of the fEPSP, to generate input-
output relations. During baseline recordings, responses were evoked at an intensity of approximately 
35% of the maximum evoked response LTP was induced using a θ-burst stimulation (4 pulses at 100 
Hz, with bursts repeated at 5 Hz and each tetanus including 3 ten-burst trains separated by 15 sec). 
oAβ42 was applied for 20 min prior to the θ-burst.  
 
Fear Conditioning. The mice‟s capacity for contextual and cued memory was tested as before (Paylor et 
al., 1994; LeDoux, 2000; Gong et al., 2006), with slight modifications. Briefly, mice were first exposed 
for 2 min to the context before the onset of a tone (a 30 s, 85 dB sound at 2800 Hz) serving as a 
conditioning stimulus (CS). In the last 2 s of the CS, mice received a 2 s, 0.50 mA foot shock 
(unconditioned stimulus, US) through the bars of the floor. Freezing, which is defined as a species-
specific defensive reaction characterized by lack of movement, associated with crouching posture was 
measured right after the end of the CS/US for 30 s using the Freezeview software (MED Associates 
Inc.). The contextual memory test was performed 24h later, by re-exposure of the mice to the same 
context and by measuring the proportion of freezing time during 5 min. To evaluate cued fear learning, 
24h after contextual testing, mice were placed into a novel context for 2 min (pre-CS test), followed by 
an exposure to the CS for 3 min (CS test), during which freezing was measured. No differences were 
found between the six genotypes in this control test (data not shown). For all the fear conditioning 
experiments, the conditioning chamber is located inside a sound-attenuating box (72 cm × 51 cm × 48 
cm). A clear Plexiglas window (2 cm × 12 cm × 20 cm) allows the researcher to digitally record the 
mouse performance with a camera placed on a tripod and connected to Freezeframe software (MED 
Associates Inc.). 
 
Radial Arm Water Maze. The test was performed as before (Trinchese et al., 2008) in a white tank filled 
with milky water, and containing stainless steel walls positioned to produce six arms, radiating from a 
central area. Spatial cues were presented on the walls of the testing room. At the end of one of the 
arms there was a clear 10 cm plexiglass submerged (1.5 cm) platform, which remained in the same 
location for every trial in one day, but was moved randomly each day. On each trial, the mouse started 
the task from a different randomly chosen arm. The mouse could not use long-term memory of the 
location of the platform on previous days, but had to rely on the short-term memory of its location in 
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the same day based on spatial cues. Each trial lasted 1 min and errors are counted each time the 
mouse entered the wrong arm with four paws, or needed more than 20 s to reach the platform. After 
each error, the mouse was gently pulled back to the start arm for that trial. After four consecutive trials, 
it was placed in its home cage for 30 min, and then administered a retention trial. Testing was 
considered complete when wild-type mice reached asymptomatic performance (below one error on 
trials four and five; 10 training days). Scores for each mouse on the last 3 days of testing were 
averaged and used for statistical analysis. All behavioral experiments were done blind to the genotype. 
Visible-platform tests to detect visual, motor or motivational impairments were performed in the same 
pool, but without arms and with the platform marked with a black flag, once the radial arm water-maze 
study was completed. Platform location was varied randomly to eliminate any contribution of external 
spatial cues. Four trials per day were given over 2 days. Each animal was allowed to swim for 1 min 
from a random location. Once the mouse reached the platform (or with help if it did not reach it on its 
own), it was allowed to rest there for 30 s. Failures to reach the platform are scored as 60 s. Data was 
recorded using a ceiling-mounted camera and analyzed with an HVS- 2020 video tracking system. 
 
In vivo PLD activity. Non-trangenic and SwAPP mice were injected intraperitoneally with 3g/kg ethanol. 
Mice were killed 1 hour post-injection. Forebrains were then removed from the mice and levels of 
phosphatidylethanol (PEtOH) produced via a PLD-specific transphosphatidylation reaction were 
measured in lipid extracts via mass spectrometry, as described below. 
  
Mass Spectrometry. Lipid extracts were prepared from mice forebrain using a modified Bligh and Dyer 
method and analyzed by LC-MS. Polar glycerophospholipids and sphingolipids were separated via a 
Luna silica column (3µm, 2mmx150mm; Phenomenex) with a solvent gradient of 100% 
chloroform/methanol/water/ammonia solution (90:9.5:0.5:0.32, by vol.) changing to 100% 
chloroform/methanol/water/ammonia solution (50:48:2:0.32, by vol.) over 40min (Pettitt et al., 
2001). Lipid species were measured using a triple quadrupole instrument ABI 4000 Q-Trap (Applied 
Biosystems, Foster City, CA) operated in multiple reactions monitoring mode (MRM). Both PA and 
PEtOH species were measured using MRM transition pair of parent ion m/z to fatty acyl chain m/z 
using instrument settings as described previously (Chan et al., 2008; Fei et al., 2008). PA levels were 
quantified by referencing to known amounts of spiked internal standard diC17-PA (Avanti Polar Lipids, 
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Alabaster, AL). PEtOH levels were referenced to spiked internal standard diC16-PEtOH (Avanti Polar 
Lipids), which was added in excess of endogenous levels of this species. 
 
Statistics. Statistical analysis was performed using two-tailed equal variance and Student‟s t test, unless 
indicated otherwise. All the experiments were performed in blind to the genotypes. 
 
Results 
Reduction in PLD2 levels blocks Aβ-induced PLD activation 
To begin to address the role of PLD in Aβ pathogenesis and to determine which of the two isoforms 
may be stimulated by Aβ, we tested whether oligomeric Aβ signaling alters the subcellular localization 
of either PLD1 or PLD2. Indeed, previous work from others has indicated that stimulation of these 
enzymes enhances their transport to and from the cell surface (Du et al., 2003; Laulagnier et al., 
2004). Pheochromocytoma cell line PC12 was transfected with constructs encoding either GFP-PLD1 
or GFP-PLD2, whose localization was analyzed after an acute treatment with 200nM Aβ42 oligomers 
(oAβ42). As expected (Du et al., 2004), in the absence of treatment or in the presence of vehicle, the 
fluorescence of GFP-PLD2 was concentrated at the plasma membrane (Fig.1A, B) while the 
fluorescence of GFP-PLD1 was more intracellular (data not shown), likely reflecting the predominant 
localization of this isoform in the Golgi complex as well as in secretory granules and endosomes 
(Jenkins and Frohman, 2005; Roth, 2008; Bader and Vitale, 2009). Incubation of PC12 cells with 
200nM oAβ42 for 5, 30, and 60 minutes did not produce an obvious effect in localization pattern of 
GFP-PLD1 (data not shown). On the other hand, while incubation of PC12 cells with oAβ42 did not 
significantly affect the localization of GFP-PLD2 after 5 min, it triggered a partial internalization of this 
probe after 30 and 60 min (Fig.1A, B). This effect was mimicked by a treatment with 2 μM ionomycin, 
a Ca2+ ionophore and a known PLD2 activator (Kim et al., 1999), and it was blocked by pre-incubation 
with 2mM EGTA, an extracellular Ca2+ chelator, indicating that the oAβ42 effect on PLD2 is Ca2+-
dependent (Fig. 1C). Based on previous work showing an activation of both the PLC and cPLA2 
pathways downstream of Aβ (Kanfer et al., 1998; Kriem et al., 2005; Berman et al., 2008; Sanchez-
Mejia et al., 2008; Oliveira and Di Paolo, 2010), we tested whether Aβ-induced GFP-PLD2 
relocalization was dependent upon PLC or cPLA2 using pharmacological inhibitors (i.e., U-73122 and 
AACOCF3, resp.). While the PLC inhibitor had no effect on the localization of GFP-PLD2, the cPLA2 
inhibitor blocked the relocalization of GFP-PLD2 in response to oAβ42, suggesting that this 
phenomenon is independent or upstream of PLC but likely downstream of cPLA2 (Fig. 1D).  
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To test whether PLD2 mediates cytotoxic actions of Aβ oligomers, we developed a mouse 
genetic model lacking PLD2 (Suppl. Fig. 1A,B). Mutant mice do not exhibit any overt phenotype. 
Western blot analysis using specific antibodies showed that the PLD2 immunoreactivity is absent and 
approximately decreased by 50% in adult brain tissue derived from Pld2–/– and Pld2+/– mice, respectively 
(Fig. 6A). In order to confirm that PLD2 ablation produces a significant decrease in total PLD activity in 
brain tissue, we developed an in vivo PLD activity assay relying on the i.p. injection of adult mice with 
ethanol and measurement of phosphatidylethanol (PEtOH) (i.e., the product of PLD) one hour post-
injection in the adult brain of Pld2+/+ and Pld2–/– mice using liquid chromatography-mass spectrometry 
(LC-MS) (Pettitt et al., 2001; Chan et al., 2008). We found a 40% decrease of PEtOH levels in the brain 
of Pld2–/– mice (Supp. Fig. 1C), thus indicating that PLD2 contributes a significant fraction of total PLD 
activity in the adult brain (with the remainder likely accounted for by PLD1).  
 
 To begin to determine the role of PLD2 in the Aβ signaling pathway, we tested whether the 
oligomeric peptide preparation used in this study (oAβ42) enhances total PLD activity in primary 
cortical neurons. Indeed, previous work from others had shown that treatment of neuronal cell lines 
with micromolar concentrations of Aβ25-35 increases PLD activity (Singh et al., 1995; Kanfer et al., 
1998; Singh et al., 1998; Oliveira and Di Paolo, 2010). Here, total PLD activity was analyzed in 
cultured neurons following metabolic labeling with [3H]-myristic acid in the presence of low 
concentrations of 1-butanol and quantification of PLD‟s transphosphatidylation product, 
phosphatidylbutanol (Fig. 2). In the absence of Aβ oligomer treatment, basal PLD activity was 
significantly decreased by 3011% and 7413% in Pld2+/– and Pld2–/– neurons, respectively. 
Remarkably, oAβ42 application led to a ~2-fold increase in total PLD activity in Pld2+/+ neurons (Fig. 2), 
an effect comparable to that obtained with 2μM ionomycin (i.e., a 9211% increase, n=6, p < 0.001). 
However, oAβ42 failed to increase this activity in Pld2+/– as well as in Pld2–/– neurons (Fig. 2), indicating 
that the PLD2 isoform is involved in the Aβ signaling cascade. 
 
 
Ablation of PLD2 blocks the suppressive effect of Aβ oligomers on LTP. 
If the activation of PLD is necessary for oAβ42-induced synaptic dysfunction, the ablation of Pld2 may 
confer a resistance against the peptide with respect to neurophysiology. To test this, the effect of 
oAβ42 on synaptic transmission was assessed in adult hippocampal slices from Pld2+/+ and Pld2–/– 
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mice, where recordings were performed in the CA1 hippocampal region after stimulation of the 
Schaffer collateral pathway. First, basal neurotransmission (input-output) was investigated and found to 
be normal in Pld2–/– slices in the absence of the peptide (Suppl. Fig. 2). Next, long-term potentiation 
(LTP) was induced by a tetanic stimulation after exposing slices from the two genotypes to 200nM 
oAβ42 or vehicle for 20 minutes. LTP in Pld2+/+ slices was comparable to that obtained in Pld2–/– slices 
in the presence of vehicle (Fig. 3). However, while oAβ42 partially impaired LTP in Pld2+/+ control 
slices, as reported before (Lambert et al., 1998; Vitolo et al., 2002; Haass and Selkoe, 2007), the 
effect of this crude oligomer preparation on LTP was strongly suppressed in Pld2–/– slices (Fig. 3), 
suggesting that the ablation of PLD2 prevents Aβ42 oligomers from exerting their synaptotoxicity. 
 
 
PLD activity is increased in the brain of a transgenic model of AD. 
To understand the in vivo relevance of the PLD pathway in an AD model, we subjected the transgenic 
line Tg2576, which expresses the Swedish APP (SwAPP) mutant (Hsiao et al., 1996) to acute ethanol 
injections, so as to conduct in vivo measurements of PLD activity as described above. We used aged 
mice (i.e., 14 month-old) for these studies, because Aβ levels are known to increase in an age-
dependent fashion in the forebrain of these animals, thus leading to well-established cognitive deficits 
(Hsiao et al., 1996). We found that total PEtOH levels are increased by 2511% (n=6, p < 0.05) in the 
forebrain of SwAPP mice relative to controls, indicating an overall enhancement of PLD activity in 
mutant animals. More specifically, there was a significant increase in a subset of molecular species of 
PEtOH (32:1, 34:2, 34:1 and 34:1) and an overall trend for an increase in the other PEtOH species 
analyzed, with the exception of 38:2 (Fig. 4; see also Suppl. Table 1 for absolute levels of PEtOH 
species). This is to our knowledge the first in vivo evidence in support of a dysfunction of the PLD 
pathway in an AD mouse model. 
 
Reducing PLD2 levels ameliorates the memory deficits of a transgenic model of AD. 
Next, the impact of Pld2 ablation on learning behavior was assessed in the SwAPP mice. To this goal, 
mice of the three Pld2 genotypes (+/+, +/–, –/–) in the transgenic (SwAPP) or non-transgenic (no 
SwAPP) background were subjected to the contextual fear conditioning paradigm, which assesses a 
form of emotional learning that requires normal amygdala and hippocampus function. In this task, an 
innocuous conditioned stimulus (tone) elicits fear response after being associatively paired with an 
aversive unconditioned stimulus (footshock). The fear response is measured by the frequency of 
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freezing behavior, which is defined as a stereotyped motionless crouching posture. For these 
experiments, 5-6 month-old mice were utilized, because our preliminary studies had shown that SwAPP 
mice, in this age category, exhibit learning deficits, which are not associated with a significant neuritic 
plaque burden and thus likely reflect the effects of soluble Aβ assemblies. Mice from all six genotypes 
did not show any major differences in the baseline levels (pre-testing). As expected, the SwAPP mice, 
unlike non-transgenic mice, exhibited little contextual fear response 24h after the pre-test, thus 
denoting an impairment in contextual learning in the presence of a normal copy number for Pld2. 
However, transgenic mice lacking one (SwAPP/Pld2+/–) or two (SwAPP/Pld2–/–) copies of Pld2 
performed better than the SwAPP/Pld2+/+ mice (Fig. 5A), suggesting that genetic ablation of Pld2 is 
protective.  
 
 Next, mice were subjected to a second learning task, the radial arm water maze (RAWM) 
paradigm, which assesses spatial working memory. In this test, mice have to find a hidden platform, at 
the end of one of six arms, remaining in the same location for every trial in one day, but moved to 
another location from day to day. For each trial, mice start the task from a different randomly chosen 
arm. After four consecutive trials mice are returned to the cage and submitted to a fifth trial (retention 
test) 30 min later. While the SwAPP/Pld2+/+ mice showed impaired memory after 10 days of training 
(see also ref. (Trinchese et al., 2008)), mice lacking one (SwAPP/Pld2+/–) or two (SwAPP/Pld2–/–) copies 
of Pld2 perform similarly as animals that do not express SwAPP (Fig. 5B), indicating that, as in the fear 
conditioning test, reduction of PLD2 was protective for the deficits induced by overexpression of the 
transgene and increased Aβ load. The six groups of mice analyzed showed no overall major differences 
in the escape latency in the visible platform task, as well as in the swimming speed (Suppl. Fig. 3) 
indicating that vision, locomotor activity or motivation did not influence the outcome of the RAWM 
testing. 
 
Reducing PLD2 levels maintains synaptic protein levels in a transgenic model of AD. 
Since a reduction or ablation of PLD2 confers protection against the deleterious effects of oAβ42 on 
LTP (Fig. 3) and of SwAPP overexpression on learning and memory (Fig. 5), a likely possibility is that 
lack of PLD2 exerts a synapse-protecting effect. To test this, levels of pre- and post-synaptic proteins 
which are known to be affected by Aβ elevation and SwAPP overexpression [see for instance (Almeida 
et al., 2005)] were investigated. We found that ablation of either one or two copies of PLD2 does not 
affect the forebrain levels of synaptophysin (presynaptic marker) and PSD95 (postsynaptic marker) in 
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the absence of SwAPP transgene. However, while expression of the SwAPP transgene leads to a 
significant decrease in the levels of PSD95 and, to a lesser extent, synaptophysin, PLD2 ablation 
restored the levels of these two synaptic proteins to normal levels, with partial phenotypes observed for 
SwAPP/Pld2+/– mice (Fig. 6). These biochemical data are in agreement with the notion that PLD2 
ablation may confer synaptic protection in the context of the SwAPP background. Because synaptic 
protein levels are not altered by the Pld2 genotype (Fig. 6) and that the electrophysiology analysis 
shows a normal input-output relationship in mutant hippocampi in the absence of SwAPP transgene 
(Suppl. Fig. 2), we speculate that the protective mechanism likely does not involve a gross increase in 
the number of functional synapses in the mutant.  
 
Effect of the APP transgene expression and PLD2 ablation on brain PA metabolism.  
To gain insight into the molecular basis underlying AD pathogenesis as well as the protection conferred 
by PLD2 ablation, we focused our analysis on PA, the product of PLD. A mass spectrometry analysis of 
mutant animals was performed covering different species of PA. Total forebrain lipids were extracted 
from 11-12 month-old Pld2+/+ and Pld2–/– mice in the presence or absence of the SwAPP transgene and 
analyzed using LC-MS. Three classes of potential lipid alterations were investigated: (i) changes 
produced by the ablation of PLD2; (ii) changes occurring in response to the overexpression of SwAPP; 
and (iii) changes reflecting interactions between the SwAPP transgene and the Pld2 genotypes. Results 
are expressed either in the form of molar percentages in a table (Suppl. Table 2) or in the form of bar 
graph relative to control brains (Pld2+/+, no SwAPP) (Fig. 7). 
 
 The data shows that ablation of PLD2 significantly decreases the levels of two molecular 
species of PA based on the different fatty acyl composition (see legend), namely, PA 32:1 (~50 %) and 
38:4 (~40%), while a trend for a decrease (~20%) was observed for two other species, PA 34:1 and 
34:0 (Fig. 4B; Suppl. Table 2). Surprisingly, the PA 32:0 and 38:2 species were upregulated (by 25% 
and ~30%, resp.), suggesting the occurrence of compensatory mechanisms in Pld2 knockout brains. 
Indeed, the total amount of PA (i.e., sum of all species measured) was overall unaffected by the Pld2 
genotype, thus denoting a tremendous plasticity in the metabolism of PA. In agreement with this 
report‟s findings showing increased PLD activity in response to Aβ application in neuronal cultures (Fig. 
2), SwAPP overexpression leads to a selective 35% increase in a low abundance, yet, functionally 
critical (Raghu et al., 2009b) (see below) species of PA, PA 34:2, out of the eleven molecular species of 
PA analyzed. Although PA 34:2 is not affected by the Pld2 genotype in the absence of the transgene, it 
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no longer accumulates in the SwAPP forebrain upon ablation of PLD2, suggesting it may be a bona fide 
product of PLD2 upon SwAPP overexpression.  
 
Reduction in PLD2 levels does not alter APP or Aβ levels in SwAPP mice 
An important question is whether the rescue of the learning performance reflects a reduction in 
amyloidogenesis. Thus a biochemical analysis of the brains from 12 month-old SwAPP/Pld2 mice was 
conducted after the RAWM test. Western blot analysis showed that full-length APP levels are not 
affected by ablation of one or two copies of Pld2 (Fig. 8A,B). Importantly, no significant differences 
were found in the levels of soluble and insoluble human Aβ1-40 and Aβ1-42 (Fig. 8C,D) and total murine 
Aβ1-40 and Aβ1-42 (Suppl. Fig. 4) upon disruption of Pld2 gene, as measured by ELISA. Overall, ablation of 
PLD2 protected from the memory deficits in the SwAPP mice, and this protection was concomitant with 
a high Aβ burden further suggesting that PLD2 acts downstream of Aβ signalling in this AD model. 
 
Discussion 
Previous studies have implicated PLD in AD pathogenesis either as a mediator of APP trafficking, 
presenilin regulation or downstream target of Aβ (Kanfer et al., 1986; Kanfer et al., 1996; Singh et al., 
1997a; Singh et al., 1997b; Kanfer et al., 1998; Singh et al., 1998; Cai et al., 2006a; Cai et al., 
2006b; Jin et al., 2007; Brandenburg et al., 2008; Liu et al., 2009; Oliveira and Di Paolo, 2010). 
Importantly, an increase in total PLD activity was reported in AD brain homogenates, using an in vitro 
enzymatic assay (Kanfer et al., 1996). However, these studies have established neither the 
pathophysiological relevance of the PLD pathway in AD in vivo models nor the precise role of PLD2 in 
AD pathogenesis. For instance, cell culture studies have established a role for PLD1, but not PLD2, in 
the trafficking of both APP and PS1 with important implications for APP metabolism and Aβ secretion 
(Cai et al., 2006a; Cai et al., 2006b; Liu et al., 2009; Oliveira and Di Paolo, 2010). Our study suggests 
that PLD2, unlike PLD1, may be a downstream target of Aβ oligomers.  
 
Although the synaptotoxic actions of Aβ oligomers are beginning to be understood, the 
underlying molecular mechanisms are still unclear. This study provides experimental and genetic 
evidence demonstrating that PLD, and PLD2 in particular, is pathophysiologically relevant in the context 
of mouse models of AD and in the synaptotoxic actions of Aβ42 oligomers. Specifically, PLD2 ablation 
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confers protection against the synapse-impairing actions of Aβ42 in an ex vivo model of synaptic 
plasticity (Fig. 3) and against the cognitive deficits and synapse impairment induced by overexpression 
of SwAPP (Fig. 5 and 6). This protective effect occurs despite high Aβ levels (Fig. 8), as observed 
previously in various other AD mouse models (Roberson et al., 2007; Sanchez-Mejia et al., 2008; 
Dziewczapolski et al., 2009; Gimbel et al., 2010). Thus, our data is consistent with scenarios whereby 
PLD2 and its enzymatic product (i) mediate key signaling cascades downstream of Aβ; (ii) regulate the 
(cell surface) availability of putative Aβ receptors at synapses; or (iii) alter the capacity of Aβ to bind to 
its putative receptors. Because a pool of PLD isozymes is associated with lipid rafts and that Aβ has a 
high affinity for these lipid microdomains (Yanagisawa, 2007; Ariga et al., 2008; Hebbar et al., 2008), 
a tantalizing hypothesis is that PLD2 ablation may disrupt the raft-dependent signalling of Aβ. 
Importantly, ablation of one or two copies of PLD2 not only reduces basal PLD activity, but it also 
blocks oAβ42-induced increase in this activity. Therefore, the protective effect may reflect either 
changes in PLD activity or a combination of both. Finally, although our data suggest that neurons 
expressing reduced amounts of PLD2 may play a central role in this protective effect, a contribution of 
other cell types, such as glial cells, cannot be ruled out. 
  
 Importantly, our results expand on previous studies showing that impairment of signaling lipids 
plays a key role in AD pathogenesis in animal models. Specifically, Aβ oligomers have been shown to 
dysregulate the PLC and PLA2 pathways with major implications for the signaling downstream of 
PI(4,5)P2 and arachidonic acid in the brain (Singh et al., 1995; Berman et al., 2008; Sanchez-Mejia et 
al., 2008). This study provides further support to the hypothesis that phospholipase signaling may be 
globally altered in AD and that Aβ-induced Ca2+-dyshomeostasis through glutamate receptors or other 
mechanisms may be underlying these changes. Indeed, we find that oligomeric Aβ affects the 
localization of PLD2 in a manner dependent upon extracellular Ca2+, thus suggesting a role for Ca2+ 
entry in the activation of three phospholipase families, PLC, PLA2 and PLD2. Here, we show that 
pharmacological inhibition of PLC does not prevent Aβ-induced PLD2 relocalization, suggesting that 
PLD2 either lies upstream or acts independently of PLC in the Aβ signalling pathway (Fig. 1D). 
Moreover, we show that PLD2 relocalization induced by oAβ42 is blocked by inhibition of cPLA2 (Fig. 
1D), in agreement with other studies showing that PLD2 activation occurs downstream of Ca2+ entry 
and cPLA2 stimulation in a lymphocytic leukemia cell line (Kim et al., 1999). More careful molecular 
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genetic/genetic approaches should provide a definitive answer concerning the crosstalk between these 
enzymes and their precise role in this cytotoxic signaling pathway. 
 
 To understand the impact on PLD activity and PA metabolism of Pld2 ablation, SwAPP 
overexpression as well as the interaction between these two genetic manipulations, we have employed 
LC-MS. The in vivo PLD activity assay relies on the measurement of PEtOH, which is the product of 
PLD catalysis in the presence of ethanol. In contrast to PA, PEtOH is a specific product of PLD and is 
very stable, due to its poor consumption by lipases (Gustavsson, 1995). Importantly, changes in 
specific molecular species of PEtOH can be correlated with those in the corresponding species of PA, 
thus providing clues on the contribution of PLD to the synthesis of specific pools of PA. Results from 
our analysis suggest that a dysregulation of PLD function and PA metabolism may be associated with 
AD pathogenesis and that specific pools of PA may be affected. Indeed, while brains from SwAPP mice 
showed an overall increase in PEtOH levels and thus total PLD activity (Fig. 4A), a more detailed 
analysis of PEtOH species showed that only a subset of species, such as PEtOH 32:1, 34:2, 34:1 and 
34:1, were increased in mutant brain (Fig. 4B; Suppl. Table 1). A direct comparison of these PEtOH 
species with the corresponding molecular species of PA (Fig. 7) revealed a remarkable and specific 
increase in both PEtOH 34:2 and PA 34:2 in the brain of SwAPP mice, and since the latter increase 
was rescued by PLD2 ablation, we speculate that this PA species may be a bona fide product of a 
hyperactivated PLD2 in the SwAPP brain. Interestingly, PA 34:2 is the only molecular species of PA that 
was found to accumulate in Drosophila melanogaster photoreceptors upon overexpression of PLD out 
of seventeen species of PA measured (Raghu et al., 2009b). Consistent with a pathogenic role of this 
lipid, overexpression of the fly ortholog of PLD in the photoreceptors results in the degeneration of 
photoreceptors. Collectively, these data suggest that increased PLD levels/activity and the resulting 
accumulation of PA 34:2 may be detrimental to cell physiology, at least in some cell types. In contrast 
to PEtOH 34:2, other molecular species of PEtOH (i.e., 36:2, 36:1, 36:0, 38:3, 38:2 and 38:1) were 
not affected by SwAPP overexpression (Fig. 4B) and the corresponding PA species were equally 
insensitive to the presence of the transgene (Fig. 7). Altogether, this combined in vivo analysis of 
PEtOH and PA species has allowed for the implication of specific PLD products in AD. However, future 
studies will be required to determine whether these lipid products are simple AD biomarkers or key 
contributors to AD pathogenesis.   
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 In addition, our LC-MS analysis uncovered interesting changes as well as some plasticity in the 
metabolism of PA as a result of PLD2 manipulation. For instance, of the two molecular species that 
were significantly decreased in the Pld2–/– forebrains (in the absence of SwAPP transgene), PA 32:1 and 
38:4, only the former is believed to be a direct product of PLD (Hodgkin et al., 1998; Pettitt et al., 
2001). Indeed, the primary source of PA 38:4 is thought to originate from DAG kinase in the PLC 
pathway (Hodgkin et al., 1998). However, ethanol injections led to the production of PEtOH 38:4 in 
mouse brain (Fig. 4B; Suppl. Table 1), suggesting that the corresponding molecular species of PC can 
be a bona fide substrate for PLD in vivo. On the other hand, hints that compensatory changes in the 
metabolism of PA can occur as a result of PLD2 ablation are suggested by the fact that knocking out 
PLD2 causes a modest, but significant increase in brain PA 32:0, a phenomenon exacerbated by 
SwAPP overexpression (Fig. 7; Suppl. Table 2). Considering the complexity of PA metabolism, adaptive 
changes can indeed be expected, perhaps allowing PLD2-deficient cells, tissues and organisms to cope 
with the deficiency of specific pools of PA that are normally produced by PLD2. Such compensatory 
mechanisms in the metabolism of PA may not be as efficient when PLD is either overexpressed (Raghu 
et al., 2009b; Raghu et al., 2009a) or hyperactivated upon stress conditions, such as during Aβ 
elevation (this study). We speculate that PLD2 ablation, which results in a 40% decrease in brain-
associated total PLD activity (Suppl. Fig. 1C), may confer protection during Aβ elevation by correcting 
some of the aberrant features of PA metabolism occurring in this condition. 
 
 Finally, our study expands on previous work showing that blocking the action of Aβ may be 
beneficial for the treatment of AD [see e.g. ref.(Gong et al., 2006; Trinchese et al., 2008)]. Collectively, 
results presented in this study identify PLD2 as a new player in AD pathogenesis and, together with the 
lack of obvious detrimental phenotypes in Pld2–/– mice, suggest that PLD2 inhibitors may be valuable 
therapeutic agents.  
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LEGENDS TO FIGURES 
Figure 1. PLD2 lies in the Aβ signaling pathway. A, PC12 cells were transfected with a plasmid 
expressing GFP-PLD2. Representative examples show internalization of GFP-PLD2 after treatments with 
200 nM oAβ42. Pictures show the fluorescence of GFP-PLD2. B, oAβ42 (200nM) was applied to PC12 
cells in cultures for 5, 30 and 60 minutes and relocalization of GFP-PLD2 was quantified as PM/cytosol 
ratio (0min: n=31; 5min: n=29; 30min: n=32; 60min: n=30). C, Effect of 30 min treatments with 
ionomycin (2μM) and EGTA (2 mM) on the localization of GFP-PLD2 in the presence or absence 200 
nM oAβ42. The number of cells analyzed was as follows: vehicle (n = 37), oAβ42 (n = 33), ionomycin 
(n = 26), EGTA (n = 33), EGTA + oAβ42 (n = 38). D, Effect of 30 min treatments with pharmacological 
inhibitors of PLC (U73122, 250 nM) and PLA2 (AACOCF3, 20 M) on the localization of GFP-PLD2 in 
the presence or absence of 200 nM oAβ42. The number of cells analyzed was as follows: vehicle (n = 
97), oAβ42 (n = 81), U73122 (n = 41), U73122 + oAβ42 (n = 42), AACOCF3 (n = 50), AACOCF3 + 
oAβ42 (n = 45). For B-D, values denote means  SEM. *, p < 0.05; ***, p < 0.001).  
 
Figure 2. Ablation of PLD2 reduces basal PLD activity and abolishes the stimulatory effect of Aβ 
oligomers on PLD activity in cultured neurons. Primary cortical cultures were labeled with [3H]myristic 
acid at day 12, treatments were performed at day 15, lipids were subsequently extracted and the ratio 
[3H]PhosphatidylButanol counts/total counts was used as a measure of PLD activity. Four-hour 
treatments with vehicle or oAβ42 200nM were performed prior to PLD activity measurement in Pld2+/+ 
(n=19 and 12 for vehicle and oAβ42 treatment, resp.), Pld2+/– (n=7), and Pld2–/– (n=5 and 7, resp.). 
Values denote means  SEM. ns - non significant. * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Figure 3. LTP is unaffected by oAβ42 in Pld2–/– hippocampal slices. There was no difference in LTP 
between Pld2+/+ slices and Pld2–/– slices in the presence of vehicle (F1,17 = 0.01, p=0.9473). Although 
Pld2+/+ slices showed a reduction of LTP following bath application of 200 nM oAβ42 (F1,16 = 5.19, 
p=0.0367, relative to vehicle), LTP was not reduced by the peptide in Pld2–/– slices (F1,14 = 0.01, 
p=0.9185, relative to vehicle). fEPSP, CA1 field-excitatory postsynaptic potential. The bar represents 
the time of bath application of oAβ42. The three arrows represent the θ-burst stimulation used to 
induce potentiation. Animals were approximately 3 month-old. Values denote means  SEM (n=8-9). 
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Note: the vehicle traces for both Pld2 genotypes (i.e., black filled triangles and circles) are largely 
overlapping.  
 
Figure 4. PLD activity is enhanced in the forebrain of aged SwAPP mice. Mice, with and without 
SwAPP transgene, were injected with 3g/kg ethanol and their forebrain lipids were extracted and 
subjected to LC-MS analysis. The production and accumulation of PEtOH was used as a reporter of in 
vivo PLD activity. Relative individual PEtOH species measured in mutant mice compared to control 
mice. The nomenclature for phospholipids fatty acid composition are denoted as total chain 
length:number of unsaturated bonds. Values denote mean  SEM (n=6).  ** p < 0.01; *** p < 0.001. 
Absolute amounts of the various molecular species of PEtOH are presented in Supplementary Table 1. 
 
Figure 5. PLD2 ablation improves learning and memory in SwAPP mice. A, SwAPP mice (Tg2576) 
were crossed with Pld2 knockout mice and the resulting offspring [Pld2+/+/no tg (n=14); Pld2+/–/no tg 
(n=14); Pld2–/–/no tg (n=11); Pld2+/+/SwAPP (n=10); Pld2+/–/SwAPP (n=12); Pld2–/–/SwAPP (n=11)] 
were subjected to training for contextual fear memory which was assessed 24h after the foot shock, 
using 5-6 month old animals. *, p < 0.05 in Student‟s one-tail t-test. B, Twelve month-old mice were 
subjected to Radial Arm Water Maze (RAWM) testing. Errors were scored in the last 3 days of testing. 
The n value was 8 for all the genotypes, except for Pld2-/-/SwAPP (n=7) and Pld2+/+/SwAPP (n=6). **, p 
< 0.01. Values denote means  SEM.  
 
Figure 6. PLD2 ablation confers synaptic protection in the forebrain of SwAPP mice. After RAWM 
testing, forebrains from 12 month-old Pld2/SwAPP mice were processed for biochemical analysis. A, 
Protein levels were evaluated by Western blot analysis of PLD2, PLD1, PSD95, synaptophysin and 
tubulin (representative blots are shown). B, Quantification of PSD95 levels by densitometric analysis. C, 
Quantification of synaptophysin levels by densitometric analysis. Values denote means  SEM. n=4. * p 
< 0.05.  
 
Figure 7. Effect of SwAPP overexpression and Pld2 genotypes on PA levels. After RAWM testing, 
forebrains from 12 month-old Pld2/SwAPP mice were processed for lipid biochemical analysis. 
Forebrain lipids were extracted from Pld2+/+ and Pld2–/– mice with and without SwAPP transgene and 
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subjected to LC-MS analysis. Relative amounts of PA species measured in mutant mice compared to 
control mice (Pld2+/+, no SwAPP). Values denote mean  SEM (n=6-8). * p < 0.05; ** p < 0.01; *** p < 
0.001. The nomenclature for phospholipids fatty acid composition are denoted as total chain 
length:number of unsaturated bonds. Absolute amounts of the various molecular species of PA are 
presented in Supplementary Table 2. 
 
 
Figure 8. Effect of SwAPP overexpression and Pld2 genotypes on APP processing. A-D, After RAWM 
testing, forebrains from 12 month-old Pld2/SwAPP mice were processed for biochemical analysis. A, 
Protein levels were evaluated by Western blot analysis of APP and tubulin (representative blots are 
shown). B, Quantification of full-length human APP levels by densitometric analysis. Values denote 
means  SEM (n = 6). C,D, ELISA analysis of the levels of soluble Aβ40 and Aβ42 (C); insoluble Aβ40 
and Aβ42 (D). Values denote means  SEM. Pld2+/+/SwAPP (n=6); Pld2+/–/SwAPP (n=8); Pld2–/–
/SwAPP (n=7).  
 
LEGENDS TO SUPPLEMENTARY FIGURES 
Supplementary Table 1. PEtOH levels in forebrain extracts from non-transgenic and SwAPP mice 
(14 month old). The relative abundance of individual lipid species is expressed as mean value ± SEM 
(n = 6). PEtOH 32:0 was not quantified as it was used as a lipid standard for the MS analysis. The 
statistical differences in relevant sample groups were analyzed using Student‟s t-test and the p values 
of these analyses are given. 
 
Supplementary Table 2. PA levels in forebrain extracts from Pld2+/+ and Pld2-/- mice with and without 
SwAPP transgene. The relative abundance of individual lipid species are expressed as mean value ± 
SEM (n = 6-8). The statistical differences in relevant sample groups were analyzed using Student‟s t-
test and the p values of these analyses are given. 
 
Supplementary Figure 1. Generation of Pld2 knockout mice. A, Gene targeting strategy - an FRT-
NEO-FRT-loxP cassette was inserted downstream of exon 15 from the Pld2 gene at the SspI site and 
the second loxP sequence was subcloned upstream of exon 13 at the MfeI site. Exon 14 contains the 
sequence encoding the first “HKD” motif of PLD2, which is essential for the catalytic activity of PLD2. 
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Pld2Flox Neo/+ mice were bred with a “deleter” strain of mice expressing Cre recombinase (Rosa26) to 
eliminate exons 13-15 and produce Pld2+/– mice. Pld2+/– mice were then intercrossed to create Pld2+/+ 
and Pld2–/– mice. The genetic background of the animals is mixed (C57Bl6, 129SVJ). B, Southern blot 
analysis of genomic DNA that was extracted from the tail of mice derived from Pld2+/– mouse 
intercrosses (right panel). DNA was digested with PstI and hybridized with a [32P] labeled-probe located 
to the 5' region (outside the targeting vector) of the targeted genomic region. The autoradiogram shows 
the wild type (+/+), knockout (–/–) and heterozygous (+/–) genotypes. The sizes of the wild-type and 
mutant alleles are indicated (4.2 kb and 11.2 kb, respectively). C, Total PLD activity was assessed 
through the measurement of total PEtOH by LC-MS analysis in the brain of adult mice one hour post-
injection with 3g/Kg of EtOH. Values denote means  SEM (n = 8-9). ***, p < 0.001.  
 
Supplementary Figure 2. Basal synaptic transmission in Pld2+/+ and Pld2–/– hippocampal slices. CA1 
field-excitatory post-synaptic potentials (fEPSPs) were recorded by placing both the stimulating and the 
recording electrodes in CA1 stratum radiatum. Summary graph of field input/output relationships for 
Pld2+/+ (white squares) and Pld2–/– slices (black squares). Values denote means  SEM (n = 8-9).  
 
Supplementary Figure 3. Visible platform task in Pld2/SwAPP mice following RAWM testing in the 
same pool with no arms. A, Summary graph of the time needed to find the visible platform. B, 
Summary graph of the swimming speed during the task. Values denote means  SEM (n = 6-8).  
 
Supplementary Figure 4. Murine Aβ levels in the forebrain of 9 month-old Pld2+/+ and Pld2–/– mice. 
ELISA analysis of the levels of murine Aβ40 and Aβ42. Values denote means  SEM (n=7). 
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Abstract 
There is accumulating evidence that aberrant lipid signaling is implicated in Alzheimer’s 
disease (AD). Phospholipase D (PLD) is a key lipid modifying enzyme that produces 
phosphatidic acid (PA), a bioactive lipid involved in multiple aspects of cell physiology, 
including signaling and membrane trafficking processes. There are two main PLD 
isozymes, PLD1 and PLD2, that in spite of catalyzing the same reaction differ in their 
structure and cellular localization. While PLD1 was shown to be involved in the 
trafficking and processing of amyloid precursor protein (APP), PLD2 was recently 
demonstrated to modulate the downstream effects of amyloid beta (Aβ). Moreover, Pld2 
ablation in a transgenic mouse model of AD (SwAPP), was shown to rescue memory 
deficits and confer synaptic protection in SwAPP mice despite a significant Aβ load. 
Initial mass spectrometry (MS)-based lipid analysis of Pld2 mutant brains in the presence 
or absence of the SwAPP transgene unmasked striking crosstalks between different PA 
species. Here, we expand the MS-lipid analysis to a wide lipidomics study including other 
lipid classes than PA, such as phosphatidylcholine (PC), diacylglycerol (DAG), 
phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), sphingomyelin (SM), ceramides (Cer), glucosyl-ceramide (Glu-
Cer), GM3 (a specific ganglioside class), cholesterol and cholesterol-ester. We found that 
overexpression of the SwAPP transgene leads to significant increase in the ganglioside, 
GM3. Remarkably, Pld2 ablation rescues GM3 levels to normals in the SwAPP 
background. This lipidomic analysis uncovered interesting lipid signaling crosstalks that 
are modulated by PLD2 in the context of AD models. 
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Introduction 
The accumulation of amyloid beta (Aβ) in the brain is one of the major hallmarks of Alzheimer‟s 
disease (AD) pathogenesis. Aβ is produced by the sequential cleavage of the amyloid precursor protein 
(APP) by β- and γ-secretases. There are two major forms of Aβ, Aβ40, the predominant cleavage 
product, and Aβ42, which is more cytotoxic and is more aggregate-prone (Small and Gandy 2006; 
Haass and Selkoe 2007; Vassar, Kovacs et al. 2009; De Strooper, Vassar et al. 2010). In the past few 
years the understanding of AD has advanced remarkably due to the development of animals models of 
the disease (Ashe and Zahs 2010). One of the major models used is the Tg2576 mouse line, which 
expresses human APP carrying the double mutation K670N and M671L found in a Swedish family with 
early onset of Alzheimer‟s disease (SwAPP), under the regulation of the hamster prion protein promoter 
(Hsiao, Chapman et al. 1996). This mouse model presents with age dependent accumulation of Aβ 
that correlates with memory behavioral deficits (Hsiao, Chapman et al. 1996). 
 
It has been shown that signaling lipids regulate various processes involved in physiologic brain 
functions. Mounting evidence has implicated the dysregulation of lipid-based signaling pathways in a 
growing number of neurodegenerative disorders. Concerning AD, the majority of these studies have 
addressed the role of cholesterol (Puglielli, Tanzi et al. 2003). However, other classes of lipids, such as 
phospholipids, have also been implicated in the modulation of key pathological processes associated 
with AD (Landman, Jeong et al. 2006; Berman, Dall'Armi et al. 2008; Sanchez-Mejia, Newman et al. 
2008; Tiago Gil Oliveira 2010). Given this amount of evidence demonstrating the importance of 
phospholipids and AD, lipid modifying enzymes, such as phospholipase D (PLD) are strong candidates 
to be involved in the pathogenesis of AD (Oliveira and Di Paolo 2010). 
PLD-mediated hydrolysis of phosphatidylcholine (PC) produces phosphatidic acid (PA), a 
bioactive lipid involved in multiple aspects of cell physiology, including signaling and membrane 
trafficking processes. There are two main PLD isozymes, PLD1 and PLD2, which, differ in their 
structure and cellular localization, although they catalyze the same reaction. This lipid regulates 
membrane dynamics and signaling processes through its intrinsic physical properties (i.e., „cone 
shape‟) and interaction with effector proteins (Jenkins and Frohman 2005; Stace and Ktistakis 2006; 
Haucke and Di Paolo 2007; Roth 2008; Raghu, Manifava et al. 2009). Localization studies suggest that 
PLD1 is predominantly localized in the Golgi complex as well as in secretory granules and endosomes 
(Jenkins and Frohman 2005; Roth 2008; Bader and Vitale 2009), while PLD2 is more concentrated at 
the plasma membrane (Du, Huang et al. 2004). The differential localization of the two PLD isozymes 
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has an impact on the way they modulate AD-related processes. While PLD1 was shown to regulate the 
trafficking and processing of amyloid precursor protein (APP) (Cai, Netzer et al. 2006; Cai, Zhong et al. 
2006; Liu, Zhang et al. 2009), our recent study has shown that PLD2 modulates the downstream 
effects of Aβ (Tiago Gil Oliveira 2010). Moreover, the same report showed that Pld2 ablation in SwAPP 
mice rescues memory deficits and confer synaptic protection, despite a significant Aβ load (Tiago Gil 
Oliveira 2010). 
 Although genomic and proteomic studies are nowadays commonly used in biomedical 
research, the field of lipidomics is now gaining increased attention, which was in part allowed by 
technological advances in liquid chromatography and electrospray ionization mass spectrometry (Wenk 
2005; Piomelli, Astarita et al. 2007). Lipidomic studies allow the characterization of a vast array of lipid 
species from a given sample and can be used in the identification of potential lipid metabolic pathways, 
which are dysregulated in a certain disease, such as neurodegenerative disorders (Wenk 2005). In the 
case of AD, this approach is starting to be employed to identify new possible drug targets, using brain 
samples from human and mouse models (Sanchez-Mejia, Newman et al. 2008; Han 2010). Lipidomics 
can also be used to suggest potential mechanistic links between specific lipid alterations (e.g., 
decreased production of PLD-derived PA) and the lipidome. Initial mass spectrometry (MS)-based lipid 
analysis of Pld2 mutant brains in the presence or absence of the SwAPP transgene unmasked striking 
crosstalks between different PA species. Here, we expanded our MS-based lipid analysis to a more 
comprehensive lipidomic study that includes lipid classes other than PA. These include PC, 
diacylglycerol (DAG), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), sphingomyelin (SM), ceramides (Cer), glucosyl-ceramide (Glu-Cer), GM3 (a 
specific ganglioside class), cholesterol and cholesterol-ester. Potential implications of alterations in the 
physiology of these lipid classes in the context of AD models are summarized in table 1. For instance, 
we found that overexpression of the SwAPP transgene leads to significant increase in the ganglioside, 
GM3 and in the total levels of PI. Remarkably, Pld2 ablation rescues GM3 and PI levels to normal in the 
SwAPP background. This lipidomic analysis uncovered interesting lipid signaling crosstalks that are 
modulated by PLD2 in the context of AD models. 
 
Materials and Methods 
Mouse strains and breeding strategy. The genetic background of the Pld2 mice is mixed (C57BL/6-
129svj). Pld2–/– females were crossed with Tg2576 males (Taconic- mixed background C57BL/6-
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SJL/N), which express human APP carrying the double mutation K670N and M671L found in a 
Swedish family with early onset of Alzheimer‟s disease, under the regulation of the hamster prion 
protein promoter (Hsiao, Chapman et al. 1996). From the F1 hybrid generation we used as breeders 
Pld2+/–/no tg females and Pld2+/–/SwAPP males. For all our animal studies we used littermate mice (or 
in some cases, mice sharing at least one parent) derived from the F2 generation. The survival rate of 
adult mice was >90% for all genotypes within the first 12 months of age (and thus the impact of Pld2 
deletion on the survival of SwAPP mice was not investigated further). 
 
Lipidomics analysis. Lipid extracts were prepared from mice forebrain using a modified Bligh and Dyer 
method and analyzed by LC-MS. Polar glycerophospholipids and sphingolipids were separated via a 
Luna silica column (3µm, 2mmx150mm; Phenomenex) with a solvent gradient of 100% 
chloroform/methanol/water/ammonia solution (90:9.5:0.5:0.32, by vol.) changing to 100% 
chloroform/methanol/water/ammonia solution (50:48:2:0.32, by vol.) over 40min (Pettitt, McDermott 
et al. 2001). Non-polar neutral lipids were separated via a ZORBAX Eclipse XDB-C18 column (5 µm, 
4.6mmx150mm, Agilent) with isocratic elution using chloroform:methanol:2% 0.1M Ammonium 
Acetate (100:100:4, by vol.) (Chan, Uchil et al. 2008). Lipid classes were quantified using a triple 
quadrupole instrument ABI 4000 Q-Trap (Applied Biosystems, Foster City, CA) operated in multiple 
reactions monitoring mode (MRM) using previously reported MRM transition pairs and instrument 
settings (Chan, Uchil et al. 2008). The signal levels of most glycerophospholipids and sphingolipids 
were converted to relative abundance levels by normalization to spiked internal standards. Neutral 
lipids were converted to relative abundance levels by normalization to total signal measured. 
 
Statistics. Statistical analysis was performed using two-tailed equal variance and Student‟s t test, unless 
indicated otherwise. All the experiments were performed in blind to the genotypes. 
 
Results 
To gain insight into the molecular basis underlying AD pathogenesis as well as the protection conferred 
by PLD2 ablation, a lipidomics analysis of mutant animals covering approximately 140 lipids was 
conducted. Total forebrain lipids were extracted from 12 month-old Pld2+/+ and Pld2–/– mice in the 
presence or absence of the SwAPP transgene and analyzed using liquid chromatography-mass 
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spectrometry (LC-MS) (Chan, Uchil et al. 2008). Three classes of potential lipid alterations were 
investigated: (i) changes produced by the ablation of PLD2, with a strong emphasis on candidate PLD 
reaction products (i.e., PA, which were already published in (Tiago Gil Oliveira 2010)); (ii) changes 
occurring in response to the overexpression of SwAPP; and (iii) changes reflecting interactions between 
the SwAPP transgene and the Pld2 genotypes. Total levels of each lipid class were analysed (Fig. 1). 
Also, results are expressed either in the form of molar percentages in a table (Table 2) or in the form 
of lipid heat maps whereby relative increases and decreases relative to control brains (Pld2+/+, no 
SwAPP) are indicated in red and green colors of varying intensity, respectively (Fig. 2). 
 
 The data shows that ablation of PLD2 significantly decreases the levels of two molecular 
species of PA based on the different fatty acyl composition (see legend), namely, PA 32:1 (~50 %) and 
38:4 (~40%), while a trend for a decrease (~20%) was observed for two other species, PA 34:1 and 
34:0 (Fig. 2; Table 2). Surprisingly, the PA 32:0 and 38:2 species were upregulated (by 25% and 
~30%, resp.), suggesting the occurrence of compensatory mechanisms in knockout brains. Indeed, the 
total amount of PA (i.e., all species measured) was overall unaffected by the Pld2 genotype, thus 
denoting a tremendous plasticity in the metabolism of PA. While no changes were found in the total 
levels of DAG, PI, SM, GM3, Cer, Glu-Cer, cholesterol and cholesterol ester, the lack of PLD2 caused an 
increase in the total levels of PS and a decrease in PC, PE and PG (Fig.1). The analysis of the lipid 
classes by species shows that almost all the PS species were significantly increased and almost all PE 
species were decreased upon PLD2 ablation, denoting a widespread effect in these lipid classes. 
Interestingly, since certain species can be hydrolyzed by PLD, total PC levels are decreased, with 
significant decreases in PC 32:1, 32:0, 34:3, 34:1 and 34:0. 
Additionally, expression of the SwAPP transgene had no significant effect in the total levels of PA, PC, 
DAG, PS, PE, SM, Glu-Cer, Cer and cholesterol. On the other hand, it was observed an increase in the 
total levels of PI, GM3 and cholesterol-esters. For both PI and GM3 the changes were observed in a 
widespread range of its lipid species, also denoting a widespread effect over these two lipid classes 
(Fig. 1; Fig. 2; Table 2). 
When combined, SwAPP expression and PLD2 ablation, quite remarkably, lead to a normalization of 
both PI and GM3 total levels (Fig. 1). 
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Discussion 
AD is a disorder whose pathophysiology has been shown to be associated with altered lipid 
metabolism. Here, we use LC-MS lipidomics to study the potential molecular basis of how PLD2 
ablation confers protection in SwAPP mice. Besides the alterations in PA that were previously published 
and discussed in (Tiago Gil Oliveira 2010), here we covered other lipid groups, such as PC, DAG, PS, 
PI, PE, PG, SM, Cer, Glu-Cer, GM3, cholesterol and cholesterol-ester. 
We found alterations in various lipid species induced by either PLD2 ablation or SwAPP 
overexpression, which are here reported and we believe these results will be important information for 
both the PLD and AD fields. However, we were particularly interested in the molecular alterations that 
could support the phenotypic observation that PLD2 ablation is protective in the SwAPP mouse model 
(Tiago Gil Oliveira 2010). Indeed, taken into account the total levels of the lipid classes, there was a 
significant increase in the levels in cholesterol-ester, PI and GM3, from which both PI and GM3 were 
rescued to normal levels in mice that both overexpressed SwAPP and were genetic ablated for PLD2. 
The lack of rescue of cholesterol-esters to normal levels, led us to speculate that the increase in 
cholesterol-esters upon SwAPP expression is not related with the memory deficits the mice present, but 
rather with another event does not change in both SwAPP/Pld2+/+ and SwAPP/Pld2-/-, such as the 
increased levels of Aβ, which are not affected by PLD2 ablation (Tiago Gil Oliveira 2010). 
 
PI is important for membrane trafficking and for the biosynthesis of other phosphoinositides (Di 
Paolo and De Camilli 2006). Since it is a precursor of phosphoinositide synthesis, the dysregulation of 
its levels might be a consequence of the dysregulation of the phosphoinoside network. In fact, the link 
between phosphoinositides and AD has been addressed in the literature. In post-mortem lipid analysis 
of brain tissue from AD-affected individuals it was reported that anterior temporal cortex of brains from 
patients with AD had significantly lower levels of PI and trends for lower levels of PI phosphate (PIP) 
and phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] (Stokes and Hawthorne 1987). Also, using 31P 
Nuclear Magnetic Resonance to study AD brain preparations, a significant reduction in PI levels was 
observed (Pettegrew, Panchalingam et al. 2001). Even though these results are somewhat 
contradictory to what we observe, they support that there is an instability in the phosphoinositide 
metabolism. This has increased relevance in light of recent work that showed the importance of other 
phosphoinositides in the pathogenesis of AD, with a reported decrease in PI(4,5)P2, which is dependent 
on the activation of PLC (Berman, Dall'Armi et al. 2008) and a reported increase in PI3-kinase activity 
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downstream of Aβ (Chiang, Wang et al. 2010). Finally, a mass spectrometry based lipidomic analysis 
in AD patients and AD mice (J20 mice that also produce high levels of Aβ) identified increased levels of 
the downstream products of the enzyme phospholipase A2 (PLA2), and that the ablation of PLA2-GIVA 
rescued synaptic and neurobehavioral dysfunction in the J20 mice (Sanchez-Mejia, Newman et al. 
2008), in a similar way as observed for PLD2 (Tiago Gil Oliveira 2010). This further shows that 
rebalancing impaired lipid signaling pathways is a valid strategy to target in the context of AD. Here, 
this lipidomic analysis, due to technical reasons, did not cover the specific analysis of other classes of 
phosphoinositides, but this result is encouraging for future studies addressing the role of the different 
players in the phosphoinositide network in the context of AD. 
Finally, the ganglioside GM3 was found to be overall increased in the SwAPP mice with a 
renormalization of its levels with PLD2 ablation. Due to technical reasons (i.e., different extraction 
conditions are required for the analysis of all the other species), other gangliosides were not measured. 
This finding was of particular interest, given the previously reported implication of gangliosides in the 
binding and aggregation of Aβ (Yanagisawa 2007; Ariga, McDonald et al. 2008)as well as in lysosomal 
storage disorders, such as Niemann-Pick Type C (NPC) (Walkley and Suzuki 2004). Additionally, 
expression of the SwAPP transgene produced a significant increase ( 2-fold) in the levels of GM3, 
consistent with a previous study (Barrier, Ingrand et al. 2007) and expanding on the notion that NPC 
may share pathogenic mechanisms in common with AD (Nixon 2004). Further emphasizing some 
analogies between lipid storage disorders and AD, levels of cholesterol esters (but not cholesterol) were 
significantly increased in the SwAPP brains ( 2-fold), consistent with current therapeutic efforts aiming 
at decreasing the activity of acyl-coenzyme A: cholesterol acyltransferase to reduce amyloidogenesis in 
AD patients (Puglielli, Tanzi et al. 2003). A prominent interaction between the SwAPP transgene and 
the Pld2 genotype was in connection with ganglioside GM3, which accumulates in SwAPP forebrain. 
When combined, SwAPP expression and PLD2 ablation lead to a normalization of GM3 levels, 
suggesting that this phenomenon may be key to the pathogenicity associated with the AD model and its 
rescue in the Pld2 null background. While future studies will address the relevance of such a 
hypothesis, our data suggest that it may not be directly connected to the metabolism of cholesterol 
esters, which accumulate in the SwAPP brains, yet, are not profoundly affected by the Pld2 genotype. 
 Previous studies have shown that impairment of signaling lipids plays a key role in AD 
pathogenesis in animal models. Specifically, Aβ oligomers have been shown to dysregulate the PLC 
and PLA2 pathways with major implications for the signaling downstream of PI(4,5)P2 and arachidonic 
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acid in the brain (Berman, Dall'Armi et al. 2008; Sanchez-Mejia, Newman et al. 2008). This study 
provides further support for the hypothesis that PLD2 signaling is altered in AD.  
 While a variety of previous studies have implicated the PLD pathway in AD pathogenesis either 
as a mediator of APP trafficking, presenilin regulation or downstream target of Aβ (Singh, McCartney et 
al. 1995; Cai, Netzer et al. 2006; Cai, Zhong et al. 2006; Brandenburg, Konrad et al. 2008; Tiago Gil 
Oliveira 2010), this study expands on the notion that PLD2, is pathophysiologically relevant in the 
context of mouse models of AD. Thus, our data is consistent with scenarios whereby PLD2 and its 
enzymatic product (i) mediate key signaling cascades downstream of Aβ; (ii) regulate the (cell surface) 
availability of putative Aβ receptors at synapses; or (iii) alter the capacity of Aβ to bind to its putative 
receptors. Results from the lipidomics analysis suggest that a dysregulation of ganglioside levels, likely 
stemming from an alteration of PLD2 function and thus PA metabolism, may be central to the 
pathogenicity associated with SwAPP overexpression and that inactivating PLD2 may counteract this 
mechanism. The recent identification of PLD2, and, to a lesser extent, PLD1, as positive regulators of 
cell surface levels of ganglioside GM1 and lipid raft-based signaling in antigen-stimulated mast cells 
(Lisboa, Peng et al. 2009) suggests that the interaction of Aβ with these lipid microdomains may be 
altered in PLD2-deficient neurons, with potentially important implications for Aβ oligomerization and 
signalling. Consistent with this idea, PLD isozymes have been reported to be raft-associated through 
palmitoylation of cysteine residues in their PH domain (Jenkins and Frohman 2005) .  
 Collectively, results presented in this study highlight PLD2 as an important player in AD 
pathogenesis. Moreover, this comprehensive brain lipidomics analysis of a widely used transgenic 
model of AD, may prove helpful as a clinical or diagnostic tool, particularly if some of the reported 
changes in lipid composition are also detected in blood cells or CSF. 
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Figure 1. Effect of SwAPP overexpression and Pld2 genotypes on forebrain lipid profile. Forebrain 
lipids were extracted from Pld2+/+ and Pld2–/–mice with and without SwAPP transgene and subjected to 
LC-MS analysis. Total levels of different lipid classes. These include phosphatidic acid (PA), 
phosphatydilcholine (PC), diacylglycerol (DAG), phosphatidylserine (PS), phosphatidylinositol (PI), 
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phosphatidylethanolamine (PE), phosphatidylglycerol (PG), sphingomyelin (SM), ceramides (Cer), 
glucosyl-ceramide (Glu-Cer), GM3 (a specific ganglioside class), cholesterol (Chol) and cholesterol-ester 
(Chol-Est). Y-axis is represented in % of relative levels to Pld2+/+/no tg. n=6-8. Values denote means  
SEM. ns - non significant. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Figure 2. Effect of SwAPP overexpression and Pld2 genotypes on forebrain lipid profile. Forebrain 
lipids were extracted from Pld2+/+ and Pld2–/–mice with and without SwAPP transgene and subjected to 
LC-MS analysis. Heat map of all lipids measured via LC-MS. The color bars, which are different for 
columns 1-2 and 3, represent the ratio of specific lipid species of mutant mice compared to that of 
control mice (Pld2+/+, no SwAPP). The absolute levels of each lipid species are presented in Table 2. 
Phosphatidic Acid, PA; Phosphatidylcholine, PC; Diacylglycerol, DAG; Phosphatidylserine, PS; 
Phosphatidylinositol, PI; Phosphatidylethanolamine, PE (a – diacyl linkage; p – 1‟-alkenyl-2-acyl 
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linkage); Phosphatidylglycerol, PG; Sphingomyelin, SM; Ceramide, Cer; Glucosylceramide, GluCer; 
Ganglioside, GM3. The nomenclature for phospholipids fatty acid composition are denoted as total 
chain length:number of unsaturated bonds while sphingolipids are denoted as sphingoid base 
residue/fatty acid residue. 
 
 
 
 
Table 1. Potential molecular and biochemical pathways affected in Alzheimer disease models. 
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Table 2. Lipid composition of forebrain extracted from WT and Pld2 KO mice with and without SwAPP 
transgene. The relative abundance of individual lipid species are expressed as mean value ± S.E.M (n = 
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6-8). The statistical differences in relevant sample groups were analyzed using Student‟s t-test and the 
p values of these analyses are given. 
 
 
References 
Ariga, T., M. P. McDonald, et al. (2008). "Role of ganglioside metabolism in the pathogenesis of 
Alzheimer's disease--a review." J Lipid Res 49(6): 1157-1175. 
Ashe, K. H. and K. R. Zahs (2010). "Probing the biology of Alzheimer's disease in mice." Neuron 
66(5): 631-645. 
Bader, M. F. and N. Vitale (2009). "Phospholipase D in calcium-regulated exocytosis: Lessons from 
chromaffin cells." Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1791(9): 
936-941. 
Barrier, L., S. Ingrand, et al. (2007). "Genotype-related changes of ganglioside composition in brain 
regions of transgenic mouse models of Alzheimer's disease." Neurobiol Aging 28(12): 1863-
1872. 
Berman, D. E., C. Dall'Armi, et al. (2008). "Oligomeric amyloid-beta peptide disrupts 
phosphatidylinositol-4,5-bisphosphate metabolism." Nat Neurosci 11(5): 547-554. 
Brandenburg, L. O., M. Konrad, et al. (2008). "Involvement of formyl-peptide-receptor-like-1 and 
phospholipase D in the internalization and signal transduction of amyloid beta 1-42 in glial 
cells." Neuroscience 156(2): 266-276. 
Cai, D. M., W. J. Netzer, et al. (2006). "Presenilin-1 uses phospholipase D1 as a negative regulator of 
beta-amyloid formation." Proceedings of the National Academy of Sciences of the United States 
of America 103(6): 1941-1946. 
Cai, D. M., M. H. Zhong, et al. (2006). "Phospholipase D1 corrects impaired beta APP trafficking and 
neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons." 
Proceedings of the National Academy of Sciences of the United States of America 103(6): 
1936-1940. 
Chan, R., P. D. Uchil, et al. (2008). "Retroviruses human immunodeficiency virus and murine leukemia 
virus are enriched in phosphoinositides." J Virol 82(22): 11228-11238. 
Chiang, H. C., L. Wang, et al. (2010). "PI3 kinase signaling is involved in Abeta-induced memory loss in 
Drosophila." Proc Natl Acad Sci U S A 107(15): 7060-7065. 
84 
 
De Strooper, B., R. Vassar, et al. (2010). "The secretases: enzymes with therapeutic potential in 
Alzheimer disease." Nat Rev Neurol 6(2): 99-107. 
Di Paolo, G. and P. De Camilli (2006). "Phosphoinositides in cell regulation and membrane dynamics." 
Nature 443(7112): 651-657. 
Du, G., P. Huang, et al. (2004). "Phospholipase D2 localizes to the plasma membrane and regulates 
angiotensin II receptor endocytosis." Mol Biol Cell 15(3): 1024-1030. 
Haass, C. and D. J. Selkoe (2007). "Soluble protein oligomers in neurodegeneration: lessons from the 
Alzheimer's amyloid beta-peptide." Nat Rev Mol Cell Biol 8(2): 101-112. 
Han, X. (2010). "Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids 
at the mild cognitive impairment stage of Alzheimer's disease." Biochim Biophys Acta 
1801(8): 774-783. 
Haucke, V. and G. Di Paolo (2007). "Lipids and lipid modifications in the regulation of membrane 
traffic." Current Opinion in Cell Biology 19(4): 426-435. 
Hsiao, K., P. Chapman, et al. (1996). "Correlative memory deficits, Abeta elevation, and amyloid 
plaques in transgenic mice." Science 274(5284): 99-102. 
Jenkins, G. M. and M. A. Frohman (2005). "Phospholipase D: a lipid centric review." Cell Mol Life Sci 
62(19-20): 2305-2316. 
Landman, N., S. Y. Jeong, et al. (2006). "Presenilin mutations linked to familial Alzheimer's disease 
cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism." Proc Natl Acad Sci 
U S A 103(51): 19524-19529. 
Lisboa, F. A., Z. Peng, et al. (2009). "Phospholipase d promotes lipid microdomain-associated signaling 
events in mast cells." J Immunol 183(8): 5104-5112. 
Liu, Y., Y. W. Zhang, et al. (2009). "Intracellular trafficking of presenilin 1 is regulated by beta -amyloid 
precursor protein and phospholipase D1." J Biol Chem. 
Nixon, R. A. (2004). "Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome 
connection fattens up." Am J Pathol 164(3): 757-761. 
Oliveira, T. G. and G. Di Paolo (2010). "Phospholipase D in brain function and Alzheimer's disease." 
Biochim Biophys Acta 1801(8): 799-805. 
Pettegrew, J. W., K. Panchalingam, et al. (2001). "Brain membrane phospholipid alterations in 
Alzheimer's disease." Neurochem Res 26(7): 771-782. 
Pettitt, T. R., M. McDermott, et al. (2001). "Phospholipase D1b and D2a generate structurally identical 
phosphatidic acid species in mammalian cells." Biochem J 360(Pt 3): 707-715. 
85 
 
Piomelli, D., G. Astarita, et al. (2007). "A neuroscientist's guide to lipidomics." Nat Rev Neurosci 8(10): 
743-754. 
Puglielli, L., R. E. Tanzi, et al. (2003). "Alzheimer's disease: the cholesterol connection." Nat Neurosci 
6(4): 345-351. 
Raghu, P., M. Manifava, et al. (2009). "Emerging findings from studies of phospholipase D in model 
organisms (and a short update on phosphatidic acid effectors)." Biochimica Et Biophysica Acta-
Molecular and Cell Biology of Lipids 1791(9): 889-897. 
Roth, M. G. (2008). "Molecular mechanisms of PLD function in membrane traffic." Traffic 9(8): 1233-
1239. 
Sanchez-Mejia, R. O., J. W. Newman, et al. (2008). "Phospholipase A2 reduction ameliorates cognitive 
deficits in a mouse model of Alzheimer's disease." Nat Neurosci 11(11): 1311-1318. 
Singh, I. N., D. G. McCartney, et al. (1995). "Amyloid beta protein (25-35) stimulation of 
phospholipases A, C and D activities of LA-N-2 cells." FEBS Lett 365(2-3): 125-128. 
Small, S. A. and S. Gandy (2006). "Sorting through the cell biology of Alzheimer's disease: intracellular 
pathways to pathogenesis." Neuron 52(1): 15-31. 
Stace, C. L. and N. T. Ktistakis (2006). "Phosphatidic acid- and phosphatidylserine-binding proteins." 
Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1761(8): 913-926. 
Stokes, C. E. and J. N. Hawthorne (1987). "Reduced phosphoinositide concentrations in anterior 
temporal cortex of Alzheimer-diseased brains." J Neurochem 48(4): 1018-1021. 
Tiago Gil Oliveira, R. B. C., Huasong Tian, Mikael Laredo, Guanghou Shui, Agnieszka Staniszewski, 
Hong Zhang, Lili Wang, Tae-Wan Kim, Karen E. Duff, Markus R. Wenk, Ottavio Arancio, Gilbert 
Di Paolo. (2010). "Phospholipase D2 ablation ameliorates Alzheimer‟s disease-linked synaptic 
dysfunction and cognitive deficits." Journal of Neuroscience. 
Vassar, R., D. M. Kovacs, et al. (2009). "The beta-secretase enzyme BACE in health and Alzheimer's 
disease: regulation, cell biology, function, and therapeutic potential." J Neurosci 29(41): 
12787-12794. 
Walkley, S. U. and K. Suzuki (2004). "Consequences of NPC1 and NPC2 loss of function in 
mammalian neurons." Biochim Biophys Acta 1685(1-3): 48-62. 
Wenk, M. R. (2005). "The emerging field of lipidomics." Nat Rev Drug Discov 4(7): 594-610. 
Yanagisawa, K. (2007). "Role of gangliosides in Alzheimer's disease." Biochim Biophys Acta 1768(8): 
1943-1951. 
  
86 
 
 
  
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 __________________________________________________________________________ 
 
Discussion, Conclusions and Future Perspectives 
  
88 
 
 
 
89 
 
Discussion, conclusions and future perspectives 
 
 Besides being a major brain constituent, lipids are also involved in multiple aspects of brain 
physiology and cell signaling. Dysregulation of these lipid signaling pathways has been associated with 
a growing number of neurodegenerative disorders, including Alzheimer‟s disease (AD). In AD, most of 
the attention has been focused on cholesterol (Puglielli, Tanzi et al. 2003), however, growing evidence 
suggests that other classes of lipids, such as phospholipids, either mediate or modulate key 
pathological processes associated with AD (Landman, Jeong et al. 2006; Berman, Dall'Armi et al. 
2008; Sanchez-Mejia, Newman et al. 2008).  
 Mounting evidence indicates that amyloid beta (Aβ) perturbs the metabolism of intracellular 
signaling lipids and that this phenomenon contributes to the pathogenic actions of this peptide 
(Hartmann, Kuchenbecker et al. 2007; Oliveira and Di Paolo 2010; Oster and Pillot 2010; Sanchez-
Mejia and Mucke 2010). In particular, it was previously shown that Aβ leads to an activation of both 
phospholipase A2 (PLA2) (Sanchez-Mejia, Newman et al. 2008), phospholipase C (PLC) (Berman, 
Dall'Armi et al. 2008) and phospholipase D (PLD) (Singh, Sorrentino et al. 1998; Brandenburg, Konrad 
et al. 2008; Oliveira and Di Paolo 2010), although in the latter case the Aβ preparations used in the 
experimental setting were of questionable pathophysiological significance. It has been shown that both 
PLA2 (specifically the GIVA isoform) and PLC are activated by calcium. Also, a wealth of studies has 
implicated calcium dysregulation in AD pathogenesis (Querfurth and LaFerla 2010). Since PLD, and 
more specifically PLD2, is also activated by calcium (Kim, Lee et al. 1999), we hypothesized that it 
could be also involved in AD pathogenesis. In particular, a study from our laboratory indicated that Aβ 
treatment leads to a trend for an increase in phosphatidic acid (PA) levels in cultured neurons 
(Berman, Dall'Armi et al. 2008). Moreover, we reasoned that PLD2 was a strong candidate to mediate 
signaling processes at the plasma membrane in response to Aβ, due to the predominant localization of 
this isozyme at the cell surface (Du, Huang et al. 2004), as opposed to PLD1, which has a more 
intracellular localization. Because PA can be produced by PLD and based on the other studies linking 
phospholipase dysregulation to AD, we tested the involvement of PLD2 in AD pathogenesis and more 
specifically, in the synaptotoxic action of Aβ oligomers. In the sections below, we highlight how we 
addressed the three aims of our thesis proposal and discuss the new avenues our study has opened.  
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Aim 1. To characterize the effects of Aβ on the PLD pathway. 
 
 We tackled this issue by conducting our studies in cell culture models. To begin to address the 
role of PLD in Aβ pathogenesis and to determine which of the two isoforms is(are) stimulated by Aβ, 
we tested whether oligomeric Aβ signaling alters the subcellular localization of either PLD1 or PLD2. 
While no obvious phenotype was observed in GFP-PLD1 transfected cells, GFP-PLD2 was relocalized 
from the plasma membrane to the cytoplasm in a Ca2+ and cPLA2 dependent way. These results also 
highlight the crosstalk between different phospholipases, a question of critical relevance that will be 
explored in future studies. Moreover, this relocalization assay can now be used for automated drug 
screening assessing PLD2 localization. The identification of small molecules that affect PLD2 
localization in response to Aβ42 may be beneficial for the treatment of AD (based on our studies), 
although these molecules would have to be validated in animal studies and assessed whether they 
effectively target PLD2 activity. Also, using primary cortical neurons we observed that while Aβ42 
oligomers lead to an increase in total PLD activity, genetic ablation of one or two copies of Pld2 blocks 
this increase in activity. The residual PLD activity in PLD2 KO (knock-out) cultures is likely dependent 
on PLD1, whose significance has yet to be determined. Studies with Pld1 KO mice, recently developed 
in our lab (Dall‟Armi and Di Paolo, unpublished observations) and by others (Elvers, Stegner et al. 
2010), will clarify this question. 
 
Aim 2. To test the effects of PLD2 ablation in an AD mouse model. 
 
 First, in order to understand the role of PLD2 activation in response to Aβ, we used an ex vivo 
preparation of the hippocampus to study long-term potentiation (LTP). This protocol was previously 
used in many studies showing that LTP is impaired by Aβ oligomers in CA1 after stimulation of the 
Schaeffer collaterals (Lambert, Barlow et al. 1998; Vitolo, Sant'Angelo et al. 2002; Haass and Selkoe 
2007). This approach is used as an electrophysiological read-out of Aβ toxicity. We observe that while 
the Pld2 wild type (WT) slices have impaired LTP after Aβ treatment, Pld2 KO slices are resistant to the 
deleterious effects of Aβ. This result not only provides further evidence for a functional relationship 
between PLD2 and the Aβ signaling pathway, but it also suggests that the synaptotoxic actions of this 
peptide require PLD2. 
 This prompted us to address the role of Pld2 ablation in an AD mouse model with the prediction 
(based on the LTP result) that it may be protective. We used the Tg2576 mouse line, which 
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overexpresses the Swedish amyloid precursor protein (SwAPP) transgene and presents with an age-
dependent increase in the levels of Aβ. A key finding was that brains from the SwAPP mice are 
associated with increased in vivo PLD activity, suggesting that PLD (and likely PLD2) are bona fide 
targets of Aβ in a more pathophysiologically-relevant setting. When crossed with the PLD2 KO mice 
(which exhibit an approximately 50% decrease in total PLD activity), Pld2 ablation had a protective 
effect in our behavioral analysis of fear contextual memory at 6 months and spatial working memory at 
12 months.  
 Previously, we observed that the treatment with oligomeric Aβ led to a trend for increased levels 
of PA in primary neuronal cultures (Berman, Dall'Armi et al. 2008). In our mass spectrometry analysis 
of the SwAPP aged mice, the total levels of PA were not changed (Fig. 1 chapter 2.2). However, the 
analysis by specific species of PA, showed that only one species was significantly increased in the 
SwAPP mice, PA 34:2 (the nomenclature for phospholipids fatty acid composition are denoted as total 
chain length:number of unsaturated bonds), which was previously associated with a neurodegeneration 
phenotype (Raghu, Coessens et al. 2009). Importantly, Pld2 ablation in the SwAPP background 
rescued the levels of PA 34:2 back to normal levels, supporting the idea that this PLD2-derived product 
may be a key factor involved in the toxic effects of Aβ. Our combined mass spectrometry analysis of PA 
and phosphatydilethanol (PEtOH) allows us to get a better understanding of PLD-derived PA. In the in 
vivo PLD activity assay in the SwAPP mice, four PEtOH species were increased, PEtOH 32:1, 34:2, 
34:1 and 34:0 (32:0 was not analysed, due to technical reasons - it was chosen as an internal 
standard in the PEtOH analysis) (Fig. 3 – chapter 2.1). Curiously, the homologous PA species were 
shown to be somewhat affected by PLD2 ablation in our lipidomic study. Besides PA 34:2 (whose 
alterations were discussed in detail in chapter 2.1), PA 32:1, 34:1 and 34:0, had all the same trend for 
decreased levels upon PLD2 ablation, either in the presence or absence of the SwAPP transgene (Fig. 
7 – chapter 2.1). While these referred species appear to be more plastic and sensitive to modulation, 
other species, such as PEtOH 36:2, 36:1 and 36:0, were not affected by SwAPP overexpression and its 
PA homologs were also not affected either by PLD2 ablation, SwAPP overexpression or both, supporting 
that these species are probably more stable. Finally, PA 38:4, was significantly decreased upon PLD2 
ablation, independently of SwAPP expression (a result confirmed by the lack of differences in the 
PEtOH 38:4 upon SwAPP expression). Since, PA 38:4 is believed to be PI(4,5)P2 derived, this analysis 
suggests that PLD2 might affect PI(4,5)P2 metabolism in a Aβ independent way. This has increased 
interest since PI(4,5)P2 levels were shown to be decreased in response to oligomeric Aβ applications in 
primary cortical neurons (Berman, Dall'Armi et al. 2008).  
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 The work from Raghu et al was based on the overexpression of the PLD homolog in drosophila, 
showing that overexpression of PLD had a toxic effect in neurons (Raghu, Coessens et al. 2009). 
Moreover, a recent work from Gorbatyuk et al showed that specifically overexpression of PLD2, caused 
severe neurodegeneration in rats (Gorbatyuk, Li et al. 2010). This toxic effect of PLD overexpression, 
somehow resembles the increased PLD activity observed in SwAPP mice. To our knowledge the 
ablation of PLD2 has not been shown to have deleterious effects. In fact, in our study it has proven 
beneficial. This body of work seems to support a deleterious effect for PLD overexpression/increased 
activity and a protective effect for PLD2 ablation, in the context of neuronal functioning. 
 Overall, the concomitant mass spectrometry analysis of PEtOH and PA levels provides 
complementary information that deepens the understanding of PLD metabolism. Due to PLD‟s high 
affinity for primary alcohols, the analysis of PEtOH levels captures the flow of potential PA pool that 
sinks as PEtOH (which is less efficiently metabolized). The mass spectrometry analysis magnifies the 
specificity of this analysis by the quantification of each PEtOH species. On the other hand, the regular 
mass spectrometry method, in the absence of ethanol treatment, captures PA levels from many 
potential sources, PLD being only one of them, thus providing a snapshot of PA metabolism. We 
believe that our analytical method represents an important conceptual advance and should be highly 
valued in future studies in the PLD field (Figure 1). 
 
 
 
 
Figure 1. A. PLD-derived PA flow, which in the presence of ethanol, sinks as PEtOH. B. “Snapshot” of 
PA levels. PA – phosphatidic acid; PC – phosphatydilcholine; PLD – phospholipase D; EtOH – ethanol; 
PEtOH – phosphatydilethanol. 
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Aim 3. To investigate the role of PLD2 in APP processing and Aβ generation. 
 
 The rationale for this aim, was that there was a reported role of PLD1 in APP trafficking and 
processing (Cai, Netzer et al. 2006; Cai, Zhong et al. 2006; Liu, Zhang et al. 2009; Oliveira and Di 
Paolo 2010). Additionally, our behavioral results showed a protective effect of Pld2 ablation in an AD 
mouse model. Thus, although our data supported a role for PLD2 downstream of Aβ signalling, 
another possibility was that PLD2 could also affect APP trafficking/processing and Aβ generation. We 
addressed this aim using biochemical analysis. First, no differences were found in murine Aβ 
(Supplementary Fig.4 - chapter 2.1) and APP levels (data not shown) in Pld2 KO adult animals. We 
then evaluated APP processing in mice that expressed the SwAPP human transgene. Human Aβ and 
APP levels were found to have no differences upon Pld2 ablation (Fig.8 - chapter 2.1). Although these 
results showed no role for PLD2 in APP processing and Aβ generation, the distribution or aggregation 
of Aβ in the brain may be affected by the lack of PLD2. As the lipidomic analysis uncovered, 
SwAPP/Pld2+/+ mice had increased levels of GM3 compared with SwAPP/Pld2-/-, and since gangliosides 
were found to interact with Aβ (Ariga, McDonald et al. 2008), this could be a possible mechanism for 
change in Aβ distribution and Aβ aggregation (discussed below). Logical experiments would be to 
assess Aβ distribution by immunohistochemical analysis and Aβ aggregation by measuring the levels 
of Aβ using conformation specific antibodies.  
 
 
Future directions 
 Overall, the main conclusion from this work is the identification of PLD2 as a new player in AD 
pathogenesis. Specifically, we show that the genetic ablation of PLD2 has a protective effect in the 
context of Aβ synaptotoxic signaling and in a AD mouse model. 
 
In search for a mechanism 
 One of the main questions that arises from this work is: “what is the exact mechanism through 
which PLD2 modulate Aβ effects?” Potentially, PLD2 may affect the various steps of Aβ oligomer 
pathogenic signaling, namely, its aggregation, interaction with membranes/receptors and Aβ 
intracellular downstream pathways. At the aggregation level as was already discussed (chapter 2.2) it 
can be potentially affected by the alterations observed in the ganglioside metabolism. Moreover, 
gangliosides, as a constituent of cellular membranes might also alter the interaction of Aβ oligomers 
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with membranes (Ariga, McDonald et al. 2008). Due to technical reasons, our lipidomic analysis only 
covered one ganglioside class, GM3. Importantly, our study reproduced the results from another group, 
which also observed an increase in GM3 levels in AD mouse models (Barrier, Ingrand et al. 2007). In 
fact, it has been shown that GM2 activator, a protein which activates β-hexosaminidase (the enzyme 
that catalyzes the reaction GM2GM3), also interacts with PLD2 leading to increased PLD activity 
levels. It would be interesting to study the relationship of GM2 activator with Aβ signaling (Sarkar, Miwa 
et al. 2001). Moreover, a full ganglioside profile analysis will be of major importance in order to study 
both the impact of increased levels of Aβ and Pld2 ablation on all different classes of gangliosides. 
Also, and in light of the ganglioside differences observed in our lipidomic analysis, it would be important 
to assess the extracellular versus intracellular location of Aβ (since our ELISA assays do not take into 
account that distinction), and within the intracellular pool, whether it is differentially distributed through 
the different cellular organelles. Since these results were observed in the context of a familial AD 
model, it would be interesting to study instead of SwAPP, mice expressing human WT APP, which 
would be more relevant for sporadic AD. Finally, similar studies should be performed with Pld1 KO 
mice, which will probably be more fruitful in a APP processing point of view, due to the results 
observed by Cai et al showing decreased amyloidogenesis upon PLD1 overexpression in cell culture 
experimental models (Cai, Netzer et al. 2006; Cai, Zhong et al. 2006). If future experiments show no 
effects of PLD2 in APP processing, it will further highlight the differences between PLD1 and PLD2, 
curiously having different implications for the same disease. 
 One interesting finding we observed is that the SwAPP/Pld2-/- mice have preserved memory even 
in the presence of high levels of Aβ. Indeed, this situation was previously observed upon the ablation of 
other genes that encode for other proteins, such as, alpha7 nicotinic acetylcholine receptor (α7nAchR) 
(Wang, Lee et al. 2000), the prion protein (PrP) (Lauren, Gimbel et al. 2009; Gimbel, Nygaard et al. 
2010), GIVA-PLA2 (Sanchez-Mejia, Newman et al. 2008) and tau (Roberson, Scearce-Levie et al. 2007; 
Ittner, Ke et al. 2010). One tentative thought is that all these players might be somehow inter-related in 
the modulation of Aβ effects. Interestingly, both α7nAchR and PrP are putative proteinaceous Aβ 
receptors. Since PLD2 has been proposed to modulate endocytic events (Roth 2008), one possibility is 
that PLD2 affects the surface availability of these Aβ receptors or the capability of Aβ to bind them. In 
fact, PLD has been shown to modulate the surface availability of a PrP related fragment (Brandenburg, 
Koch et al. 2007). Concerning GIVA-PLA2, we show in this thesis that it lies upstream of PLD2 in the 
Aβ signaling pathway, confirming previous results in leukocytes (Kim, Lee et al. 1999). This opens new 
lines of research, specifically in trying to understand how the different phospholipases regulate each 
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other. It would be interesting to study PLD metabolism upon PLA2 modulation and also the effects of 
PLD2 modulation in PLA2 metabolic pathways. The PLA2-Aβ-dependent pathway has been addressed 
and namely, PKC, p38, and MEK/ERK pathways were shown to be involved, and importantly, the anti-
inflammatory inhibitors of cyclooxygenase-2 were shown to protect from Aβ toxic effects (Kriem, 
Sponne et al. 2005). Also, Mucke‟s group has shown that GIVA-PLA2 ablation protected from Aβ 
neurotoxicity, an effect that was shown to be mediated by AMPAR internalization (Sanchez-Mejia, 
Newman et al. 2008). As for the putative Aβ receptors and in light of the crosstalk between PLA2 and 
PLD2, PLD2 might also potentially mediate AMPAR internalization with potential impact in protecting 
from Aβ excitotoxic effects. Finally, the ablation of tau was shown to be protective in two different 
amyloidogenesis mouse models (Roberson, Scearce-Levie et al. 2007; Ittner, Ke et al. 2010). Tau 
ablation was shown to protect from excitotoxicity to which the AD mice were shown to be more 
susceptible. The molecular mechanism was further dissected and it was shown that tau binds Fyn and 
this interaction leads to stabilization of the NMDAR/PSD95 complex. In the absence of tau, the 
NMDAR/PSD95 interaction was less stable leading to excitability protection in the amyloidogenesis 
mouse models. It was further shown that a tau independent manipulation of the NMDAR/PSD95 
interaction also led to a protective effect (Roberson, Scearce-Levie et al. 2007; Ittner, Ke et al. 2010). It 
is thus logical to speculate that PLD2 might modulate any of these molecular players: tau, Fyn, NMDAR 
or PSD95, or its molecular interactions. If this is the case, one important experiment to perform is to 
assess if Pld2 KO mice are less susceptible to drug-induced excitotoxicity (as tau KO mice are). This 
would support a more basic role for PLD2 with an impact at the circuit/systems level and potential to 
be studied in the context of multiple neurological diseases. 
 
In conclusion, in addition to fulfilling the initial aims proposed for this thesis, the body of work produced 
raised many more questions that are of the most interest to be addressed in the future. These are 
highlighted below: 
 
1. An obvious future direction to pursue is to initiate drug trials with PLD2 specific inhibitors. Initial 
studies should be started with AD animal models and if the results are encouraging, 
experimentation should be expanded to clinical trials in humans. 
 
2. The exact mechanisms through which PLD2 acts and Aβ leads to PLD activation are still elusive. 
The exhaustive characterization of these mechanisms will be key for the understanding of AD 
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pathophysiology and for a potential role of PLD2 in other neurodegenerative diseases. 
 
3. The crosstalk of PLD2 with other signaling pathways (such as the PLC and PLA2 pathways) 
should also be addressed in more detail. 
 
4. Our lipidomic analysis has produced a vast amount of data that can potentially lead to many 
more lines of research. An immediate one is the study of the potential role of gangliosides in 
AD.  
 
5. Another important question is the study of the effect of Pld1 ablation and the study of the impact 
of ablating both isoforms, Pld double KO. The characterization of the effects of pharmacologic 
agents that inhibit either PLD1, PLD2 or both will complement the genetic studies. 
 
 
6. Finally, this work has provided major technical advances in the field of PLD, specifically in 
understanding PLD in vivo activity using mass spectrometry. Previous studies that have been 
performed using primary alcohols to inhibit PLD should be readdressed with the new 
genetic/pharmacological tools.  
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